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Abstract  
 
Alzheimer's disease (AD) is the most common form of neurodegenerative disorder that 
progresses with aging. The AD brain is characterized by a massive loss of neurons and 
synapses. Two key hallmarks of AD are the aggregation of the amyloid-β (Aβ) peptide as 
plaques and of the microtubule-associated protein Tau as neurofibrillary tangles. Under 
physiological conditions, Tau is mainly localized to the axon of neurons, with low levels of 
expression found in dendrites and spines. Under disease conditions, Tau is 
hyperphosphorylated and accumulates in the somatodendritic domain of neurons including 
spines. Recent data suggest that dendritic spine-targeted Tau disrupts synaptic function 
and causes synaptic loss long before neurofibrillary tangle formation and neuronal loss 
occurs.  
 
Fyn is a non-receptor tyrosine kinase that mainly targets to the postsynaptic membrane in 
spines. Fyn interacts with and phosphorylates Tau and this interaction has a critical role in 
mediating Aβ toxicity. Understanding how Tau and Fyn are targeted to the dendritic spine 
and how their trafficking and interaction is regulated under both physiological and 
pathological conditions is critical for understanding how AD is initiated in the synapse and 
for developing novel therapeutic approaches to delay, halt or treat AD.   
 
Fyn phosphorylates Tau mainly at Tyr18; however, it is unclear how tyrosine 
phosphorylation of Tau by Fyn affects serine/ threonine phosphorylation. In the first part of 
my thesis, I have generated a transgenic animal model that expresses constitutively active 
Fyn and studied the functional consequence of Fyn activation, especially for Tau. We 
found that FynCA animals showed premature lethality and hyperactive phenotypes 
reflecting the synaptic over-excitation by Fyn as expected. A biochemical analysis of 
isolated synaptosomes revealed increased levels of the NMDA receptor subunit NR2b 
phosphorylated at residue Y1472, and of Tau phosphorylated at the 12E8 phospho-
epitope S262/S356. Besides, Tau phosphorylation at the AT8 epitope S202/T205 was 
strongly increased in FynCA mice as revealed by both immunohistochemistry and Western 
blot analysis. Our results indicate that an increased tyrosine kinase activity of Fyn has a 
role in serine/threonine-directed phosphorylation of Tau, which may contribute to the 
tauopathy in AD.  
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Under physiological conditions, low levels of Tau are targeted to dendritic spines in a 
process that is regulated by synaptic activity and Aβ levels. It has also been reported that 
hyperphosphorylated Tau mislocalizes into the spine, although it is not clear what kind of 
phosphorylation is required. In order to understand how Tau enters the spines and the role 
of Fyn in dendritic spine targeting of Tau, we performed an extensive mutagenesis study 
by overexpressing different mutant forms of Tau in cultured wildtype or FynKO neurons. 
Our results revealed that the spine localization of Tau is facilitated by deletion of the 
microtubule-binding repeat domain. Distinct pseudophosphorylation at AD related sites 
AT180(T231/S235), 12E8(S262/S356), or PHF1(S396/S404) but not S422 to glutamic acid 
were sufficient to target Tau into the spine.  
 
Most in vitro and in vivo models investigating Tau use overexpression approaches that 
have shown non-specific expression of Tau in all cellular compartments (in contrast to 
endogenous Tau that mainly localized in axons), indicating that over-expression may 
compromise Tau trafficking and cause artifacts. To overcome this drawback and study the 
trafficking of Tau at more relevant endogenous levels, we have also successfully created a 
Tau-mEOS2 knock-in animal using the genome editing tool TALEN. We determined the 
subcellular localization of Tau-mEOS2 using live cell imaging which clearly showed that at 
an early developmental stage, Tau-mEOS2 followed a proximo-distal gradient in axons 
that was similar to that of endogenous Tau in neurons obtained from wild-type mice. We 
have also confirmed the presence of Tau in the somato-dendritic compartment, but not the 
nucleus. Using the FRAP assay, we further revealed that the mobility of Tau in dendrites 
and axons of Tau-mEOS2 neurons was reduced compared with that of overexpressed Tau. 
Together, our study presents Tau-mEOS2 mice as a novel tool for the study of Tau in a 
physiological and a pathological context. 
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1.1. Alzheimer’s disease and frontotemporal dementia 
 
1.1.1. Alzheimer’s disease 
 
First described in 1907 by the German psychiatrist and neuropathologist Alois Alzheimer, 
Alzheimer's disease (AD) is now known as the most common form of senile dementia. More than 
35 million people worldwide are currently living with AD, a number that will further increase to 
more than 106 million by 2050, if an effective treatment is not developed. AD is a progressive 
neurodegenerative disorder that is characterized by the loss of neurons and synapses in the central 
nervous system. The symptoms of AD include the loss of short- and long-term memory, changes in 
personality, and a difficulty in performing tasks in social and/or work settings, which eventually 
leads to admission to a nursing home and ultimately, death.  
 
Currently, there is no cure that would prevent, halt or reverse AD, partly because its cause is not 
well understood. The key histopathological hallmarks of AD are amyloid plaques and 
neurofibrillary tangles (NFTs). The major component of amyloid plaques is a 37-43 amino acid 
polypeptide termed Aβ that is processed by proteolytic cleavage of the larger amyloid precursor 
protein, APP (encoded by APP gene), by the combined action of β- and γ-secretase. The major 
peptides generated by these enzyme activities are Aβ40 and Aβ42, with the latter being more 
amyloidogenic. The second histopathological hallmark of AD are the NFTs that are found in cell 
bodies and apical dendrites and are mainly composed of hyperphosphorylated, aggregated 
assemblies of the protein Tau [1], which is encoded by MAPT gene. 
 
AD is genetically complex and heterogeneous. The majority of cases are sporadic, and less than 
1% of all cases are familial, caused by mutations in APP itself, and in the PSEN1 and PSEN2 
genes, which encode the γ-secretase complex components presenilin 1 and 2, respectively. 
Surprisingly, no mutations in the MAPT gene have been identified so far in AD. The major risk 
factor of AD is age. Other risk factors include head injury, lack of education, cerebrovascular 
disease, diabetes and obesity to name a few. 
 
The most significant genetic risk factor found in sporadic late-onset AD is the ApoE4 allele of the 
ApoE gene, which encodes a lipoprotein transporter termed apolipoprotein E. Carriers of two 
ApoE4 alleles have a twentyfold higher risk of developing AD, compared with those who carry 
only ApoE2 or ApoE3 alleles. ApoE4 probably has both Aβ-dependent and Aβ-independent roles 
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in AD pathogenesis.  It is believed that an imbalance in the production and clearance of Aβ can 
cause the build-up of amyloid plaques. In familial cases, mutations in PSEN1 and 2 and APP are 
associated with an increased production of Aβ more generally, or an increased production of the 
more amyloidogenic form, Aβ42. In sporadic cases of AD, ApoE4 impairs Aβ clearance resulting 
in an increased accumulation of Aβ42, thus increasing the vulnerability to develop AD in 
individuals carrying that allele. In addition, neuronal ApoE4 undergoes proteolytic cleavage to 
generate truncated neurotoxic fragments that cause Tau pathology and mitochondrial dysfunction 
[2].  
 
1.1.2. Frontotemporal dementia 
 
Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by 
the progressive loss of neurons in the frontal and temporal lobes. FTD is the second most common 
form of dementia and the most common form of dementia at young age, more than 50% of 
dementia cases before age 60 are FTD. Currently, as for AD, there is no effective treatment 
available for FTD. Symptoms of FTD include behavioural and personality changes, as well as 
language and communication difficulties together with cognitive impairments. 
 
Frontotemporal Lobar Degeneration (FTLD) is the term referring to the neuropathology of FTD. 
Based on their pathology, there are three subtypes of FTLD: FTLD-Tau (with inclusions 
containing tau), FTLD-TDP (inclusions containing TAR DNA-binding protein 43 (TDP-43) 
conjugated with ubiquitin) and FTLD-FUS (containing aggregates of Fused in Sarcoma).  FTLD-
tau or FTD with Parkinsonism linked to chromosome 17 (FTDP-17) is characterised by tau-
positive inclusions that are composed of hyperphosphorylated tau in both neurons and glial cells. 
Compared with AD, there are more genetic causes in FTD. About 40% of all FTD cases are 
familial. More than 40 mutations have been found associated with FTD in the MAPT gene. 
Mutations in other genes such as PGRN, and C9ORF72 have also been found to cause FTD [26]. 
 
To better understand the role of Aβ and Tau in AD and FTD, a host of experimental rodent models 
have been developed that reproduce the major aspects of the neuropathological characteristics of 
these diseases [3]. One of the most commonly used and extensively characterized AD mouse 
models is the APP23 strain that expresses human APP together with the Swedish double mutation 
(KM670/671NL) [4]. These mice show AD pathology such as β-amyloid plaques, neuronal loss 
and deficits in spatial memory. Although in these APP mutant mice, hyperphosphorylated tau was 
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found in dystrophic neurons, no NFTs were observed.  The tau pathology has been modelled in 
transgenic mouse models by expressing a range of FTD mutations (such as P301L, P301S or 
R406W) controlled by various neuronal promoters, resulting in strains such as JNPL3 or pR5 [5,6]. 
These mice reproduce Tau aggregation, NFT formation and neuronal loss modelling the human 
pathology. These finding strongly suggest that APP and MAPT gene, which encode for proteins 
deposited in plageuqes and NFTs respectively, has a causal role in AD and FTD. AD and FTD 
rodent models have now become widely used tools to both study pathogenic mechanisms, as well 
as for testing therapeutic approaches.  
 
1.2 The microtubule-associated protein Tau 
 
Tau belongs to the family of microtubule-associated proteins (MAPs) that promote the assembly 
and stabilization of microtubules (MTs). The protein is mainly expressed in neurons of the central 
nervous system, but is also found in astrocytes and oligodendrocytes and even lymphocytes, albeit 
at low levels. Tau is encoded by the MAPT (microtubule-associated protein Tau) gene that in 
humans is located on chromosome 17. In the human CNS, there are six major isoforms that are 
generated through alternative splicing of exons 2, 3 and 10. They differ by the number of amino-
terminal inclusions (0N, 1N or 2N) and the number of microtubule-binding domains (MBD) (3R or 
4R) (Fig 1.1). The expression of the different Tau isoforms is developmentally regulated, with the 
fetal human brain only expressing 3R Tau and the adult human brain expressing 4R and 3R Tau at 
a 1:1 ratio [7]. 4R tau isoforms have shown a higher ability to promote microtubule polymerization 
than 3R tau [8], and any imbalance of the 4R/3R ratio is supposed to cause MT dysregulation and 
increase the propensity to form fibrillar aggregates [9]. 
 
Tau contains four major domains, the N-terminal projection region, a proline-rich region, the MBD 
and a C-terminal region (Fig 1.1).  The binding of Tau to microtubules is thought to occur through 
its MBD. 
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Figure 1.1 
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Figure 1.1, Schematic representation of human Tau-encoding MAPT gene. Tau isoforms, and 
domain structure.  In human central nervous system, six major isoforms are expressed, that are 
generated through alternative splicing of exons 2, 3 and 10. They differ by the number of N-
terminal inclusions (0N, 1N or 2N) and the number of microtubule-binding domains (MBD) (3R 
or 4R). Tau can be divided into the projection domain and the assembly domain or alternatively 
subdivided into 4 domains: an N-terminal acidic region, proline-rich region (PXXP motif) , the 
MBD, and the C-terminal tail.  
 
The proline-rich domain of Tau contains 7 PXXP motifs, through which Tau can bind to the SH3 
domains of other proteins, such as the Src family tyrosine kinase, Fyn. Tau can also bind to cell 
membranes by means of its N-terminal region, probably through an interaction with the membrane 
lipid binding protein, Annexin A2 [10].  
 
Tau is a highly phosphorylated protein with 80 potential serine and threonine and five tyrosine 
phosphorylation sites of which approximately 30 have been found to be actually phosphorylated in 
the adult human brain. Tau has been found to be phosphorylated by many kinases, including 
glycogen synthase kinase 3β (GSK3β), calmodulin-dependent protein kinase II (CaMKII) cyclin-
dependent kinase 5 (Cdk5), microtubule-associated regulatory kinase (MARK) and Fyn. In 
addition, the serine/threonine-specific protein phosphatase 2A (PP2A) has been revealed as a major 
phosphatase that dephosphorylates Tau. The phosphorylation status of Tau is determined by a 
balance of Tau kinase and phosphatase activities. An imbalance of these activities will cause Tau 
hyperphosphorylation and thereby cause Tau aggregation. In AD patients, the level and activity of 
PP2A is reduced [11]. The phosphorylation level of Tau has been closely linked to its binding 
capacity to microtubules. Phosphorylation of Tau in the MBD and adjacent regions reduces its 
binding capacity and is associated with Tau aggregation in AD and FTD.  Inhibiting Tau kinases 
using GSK3 inhibitors such as lithium [12], or activating the Tau phosphatase PP2A using sodium 
selenate dramatically reduces Tau phosphorylation in transgenic animal models with a Tau 
pathology [13], indicating that reducing Tau hyperphosphorylation might be an effective approach 
to treat AD in humans.  
 
1.2.1 Subcellular distribution of Tau and Tau trafficking 
 
In neurons, under physiological conditions, Tau is mainly targeted to axons, while another family 
member of the microtubule-associated proteins, MAP2, is mainly targeted to dendrites. How 
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MAP's polarized distribution is mediated and regulated is still under debate. Postulated 
mechanisms (at least in rodents) include differential mRNA trafficking of MAPT or MAP2, 
selective protection of Tau or MAP2 protein from degradation, local regulation of microtubule 
binding, and a retrograde barrier at the axon initial segment (AIS) that allows Tau to only be 
transported in one direction [14-16].  
 
It was not until recently that our team identified Tau expression also in the dendrites, although at a 
much lower level compared with axonal Tau [17]. The role of Tau in dendrites however is only 
understood to some degree. Our laboratory previously showed that Tau has a role in targeting Fyn 
to the spine where it phosphorylates the NMDA receptor subunit NR2b which then facilitates the 
formation of an excitotoxic complex with the scaffolding protein PSD-95. Under disease 
conditions, Tau is hyperphosphorylated and relocalised from the axon into the somatodendritic 
compartment, potentially disrupting motor protein functions and axonal transport, as well as 
causing excitotoxicity and synapse loss and neurodegeneration [17,18]. 
 
Although NFTs are prevalent in AD, no MAPT mutations have been found in familial AD cases. 
However, in patients with FTD, pathogenic mutations have been identified in the Tau-encoding 
MAPT gene, suggesting that neurotoxicity can also be caused by Tau pathology, in the absence of 
an Aβ plaque pathology [19]. In AD, the amyloid cascade hypothesis posits that Tau pathology is 
driven by Aβ. Evidence from in vitro experiments using primary neuronal cultures have shown that 
applying Aβ derived from human AD brains induced Tau aggregation and caused neuronal demise, 
while the absence of Tau prevented toxicity [20]. In murine models, the evidence that Tau 
knockout can rescue Aβ neurotoxicity strongly supports the notion that Aβ is upstream of Tau and 
that its toxicity is mediated through Tau [17,21]. 
 
1.3. The Src tyrosine kinase, Fyn 
 
Fyn is a non-receptor tyrosine kinase that belongs to the Src family kinase (SFK). Of the three Fyn 
isoforms, isoform 1 is the one that is most highly expressed in brain. Fyn contains six domains, the 
N-terminal SH4 domain, a so-called unique domain, the SH3 domain, SH2 domain, SH1 domain, 
and a C-terminal regulatory domain. The SH4 domain contains myristoylation and palmitoylation 
sites that are critical for Fyn's targeting to the plasma membrane [22]. The unique domain is less 
conserved between different SFK and may determine target selectivity. The SH3 domain interacts 
with the proline rich PXXP motif of target proteins including Tau and MAP2, and the SH2 domain 
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binds to the PDZ domain of additional proteins such as PSD95 as well as phosphorylated tryrosine 
residues of target proteins including Tau. The SH1 domain is the catalytic domain that 
phosphorylates its substrate. Study from Fyn knockout mice show disrupted hippocampal 
structures, severe defects in myelination, deficits in long-term-potentiation and impaired spatial 
learning, suggesting that Fyn has important neuronal functions that include brain development, 
synaptic transmission and plasticity. [23]. 
 
The regulation of Fyn in synaptic transmission and plasticity is mainly through AMPA and NMDA 
receptors. Fyn regulates AMPA and NMDA receptor trafficking through tyrosine phosphorylation 
of the GABA γ2 subunit and the NMDA receptor subunit NR2B, respectively. Fyn can also 
directly interact with PSD95. This interaction facilitates the Fyn-mediated tyrosine phosphorylation 
of NR2A and NR2B, which then stabilizes the NMDA-PSD95 complex, thus enhancing NMDA 
currents. In AD, binding of Aβ to the postsynaptic target prion protein, PrPc, has been shown to 
activate Fyn and thereby induce excitotoxicity [24].   
 
The targeting of Fyn to the cell membrane is regulated by lipid modification at the N-terminal SH4 
domain [25]. In neurons, Fyn is also localized to the spines (Fig. 2.2). It is unclear how Fyn is 
targeted into dendritic spines, whether it is through transportation by motor proteins such as kinesin 
or simply by lateral diffusion along the cell membrane, and then retained in the PSD through 
binding to anchored proteins such as PSD95. Our laboratory’s previous research showed that in 
Tau knockout mice, the localization of Fyn to dendrites is largely reduced [17], indicating that 
dendritic spine targeting of Fyn is Tau dependent. However, how Tau mediates dendritic targeting 
of Fyn is still unclear.  
 
1.4. Tau-Fyn interaction and its implication in AD 
 
The interaction of Tau and Fyn is critical in mediating Aβ toxicity. Both Tau and Fyn knockout 
mice have been found to rescue Aβ toxicity in AD mouse models suggesting that Tau and Fyn are 
both downstream of Aβ. Further evidence from our laboratory and others has shown that Fyn is a 
key player together with Tau and Aβ in disease, establishing what can be called a 'toxic triad'. As 
mentioned above, under normal conditions, Tau is mainly localized to axons, but a smaller amount 
of Tau also interacts with Fyn and is targeted into the dendritic spines together with Fyn. Under 
disease conditions, redistribution of hyperphosphorylated Tau from the axon into the 
somatodendritic compartment is thought to increase Tau-dependent sorting of Fyn to the dendrites, 
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leading to an over-excitation of the NMDA receptor. Indeed, we have shown that both the loss of 
Tau and overexpression of a truncated Tau protein lacking the MBD but still capable of binding 
Fyn, can prevent postsynaptic targeting of Fyn, and thereby NMDA-dependent excitotoxicity and 
memory impairment. 
 
Tau interacts with Fyn at least in two ways. Firstly, although Tau is mainly phosphorylated on 
serine and threonine residues, it also contains five tyrosine residues (Tyr18, 29, 197, 310, 394). 
Tyr18 is phosphorylated by Fyn, and the phosphorylated motif interacts with Fyn via Fyn’s SH2 
domain. Secondly, Tau contains seven PXXP motifs, of these, the seventh proline-rich RTPPKSP 
motif has been shown to be crucial for the interaction with the SH3 domain of Fyn [26]. 
Interestingly, this motif is also critical in the interaction of Tau with the phosphatase PP2A, which 
exists as a heterotrimeric holoenzyme complex. It has been shown recently that the PP2A regulatory 
subunit Bα binds to and dephosphorylates Tau, and thereby regulates microtubule stability [27]. 
When Fyn is bound to the (seventh) proline-rich RTPPKSP motif that is conserved in both Tau 
and MAP2, this inhibits the interaction of PP2A/Bα with either Tau or MAP2. The corresponding 
synthetic RTPPKSP peptide, but not the phosphorylated RpTPPKSP version, competes 
with Tau and MAP2 for binding to PP2A/Bα. This finding is remarkable because the down-
regulation of PP2A/Bα and the deregulation of Fyn/Tau interactions have been linked to enhanced 
Tau phosphorylation in AD. MAP2 is mainly a dendritic protein as mentioned above. Why MAP2 
cannot compensate for the absence of Tau in Tau knock-out mice and target Fyn to the dendritic 
spine is not understood, especially as both MAP2 and Tau have been shown to efficiently bind to 
Fyn [28].  
 
1.5. TALEN and Genome editing technology 
 
In order to study the function of genes and determine how the genotype affects the phenotype, 
methods are available such as the overexpression of the gene of interest for gain-of-function studies, 
and RNA interference (RNAi) or gene knockouts for loss-of-function studies.  However, any 
overexpression is un-physiological, and the knockdown of genes by RNAi is temporary, incomplete, 
and often has unpredictable off-target effects. Traditionally, the generation of knockout animals 
requires embryonic stem cell-based homologous recombination for gene targeting. Gene targeting 
by homologous recombination is of low efficiency and is a time consuming strategy and is only 
available for  a limited number of organisms such as mice and yeast [29]. The development of novel 
genome editing tools in recent years, however, is overcoming these shortcomings opening new 
avenues for functional genomic studies. Genome editing is a technique that utilizes modified site-
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directed nucleases to precisely edit any DNA sequence at the genomic level, in a wide range of 
organisms and cell-types.  The site-directed nuclease is a chimeric protein that is composed of the 
sequence-specific DNA-binding domains (the area that one wants to target) fused with a 
nonspecific DNA endonuclease.  
 
The sequence-specific DNA-binding domain allows targeting of a precise, defined location in the 
genome. Upon binding to the target sequence, the nuclease domain induces a double-strand break 
(DSB) that stimulates the cellular DNA repair machinery, including error-prone non-homologous 
end joining (NHEJ) as well as homologous recombination (HR) provided that a template exists. 
When DSB is induced in the first few exons of a target gene, following NHEJ, INDEL (insertion of 
deletion) will happen, leading to an open reading frame shift of the target gene, which thus results 
in a complete knockout. It has been reported that a DSB increases the frequency of HR by a factor 
of a hundred to a thousand. As a template for HR a donor construct is generated that bears locus-
specific homologous arms (>500bp) with a non-homologous sequence (such as a fluorescent protein 
cassette if one wants to tag the gene of interest in situ) located in between (Fig 1.2). Donor 
constructs with homologous arms as short as 50 bp and single-strand DNA oligonucleotides of 
between 30 and 50 bp have also been used, by co-delivery with site-directed nucleases, to 
efficiently induce mutations, deletions, or insertions at the particular genetic locus.  
 
At least three genome editing techniques have been developed in recent years. These include the 
zinc-finger nucleases (ZFNs), the Transcription activator-like effector nucleases (TALENs), and 
RNA-guided nucleases Clustered Regularly Interspaced Short Palindromic Repeats associated 
nuclease (CRISPR-Cas) [30].  
 
TALEN (the method that has been used by us) combines a re-engineered transcription activator-like 
effectors (TALEs) as a DNA-binding-adaptor and FokI endonuclease as a molecular scissor. TALE 
is a naturally occurring effector protein used by the plant pathogenic bacterium Xanthomonas sp. to 
modulate the expression of the host genome and assist in its survival. The core of TALE is a DNA-
binding domain that consists of a varied number of tandem repeats (monomers), with the size of a 
monomer being 34 amino acids, and the number of monomers ranging from 1.5 to 33.5. Both the 
sequence and the size of the monomers is highly conserved. The monomers differ mainly by their 
12th and 13th amino acid, termed repeat variable di-residues (RVD) (Fig 1.3).  
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Figure 1.2 
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Figure 1.2, Principle of Genome Editing Using Site-specific Endonuclease  A programmable 
site-specific endonuclease (ZFN, TALEN or CRISPR-Cas9) targets and incorporates a double-
stranded break (DSB) on the genomic DNA. In the absence of a repair template, the cell will 
repair the DSB by non-homologous end joining (NHEJ) machinery, randomly inserting and/or 
deleting (indels) DNA base pairs at the target site, resulting gene disruption. In the presence of a 
DNA donor template containing left and right sequences homologous to the regions closed to the 
DSB, cell will repair the DSB through homologous recombination (HR) pathway, resulting in 
incorporation of the donor sequence into the editing site of genomic DNA. 
 
 
The DNA binding-specificity of each TALE is based on a simple cipher rule that specifies the target 
nucleobase of each RVD in a one-to-one manner (NI = A, HD = C, NG = T, NN = A or G), thus the 
sequence of TALE arrays determines the targeted DNA sequence. This single TALE-DNA binding 
capacity makes the system superior to the older zinc finger technology. Theoretically, one can target 
any DNA sequence in any genome, with only a few restrictions. Firstly, the first TALEN binding 
site always has to start with a T. Secondly, the off-target effect needs to be taken into consideration 
as the TALEN can tolerate a 1~2 nucleotide mismatch. Finally, the activity of TALEs may rely on 
the accessibility of the DNA sequence, which could be affected by the chromatin state [30]. 
 
 
Figure 1.3 
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Figure 1.3, Schematic representation of TALE and TALEN. TOP, Structure of the nature 
occurring TALEs. (NLS = nuclear localization signal, AD = activation domain) Bottom, 
Structure of reengineered TALEN. It contains a DNA binding domain and a FokI endonuclease 
domain. Upon binding of TALEN to their genomic targets in a proper distance (14~20bp 
spacer), FokI from the left and right TALENs could form an active dimer and generate a double-
strand bread in the middle. 
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1.3. Aims and Hypotheses  
 
1.3.1 Aim1: Establishing Fyn constitutive active (FynCA) transgenic animals as a model of 
Fyn toxicity. 
 
Hypothesis A: Based on previous work by our group [17] and others [31] we hypothesize that 
over-expression of FynCA will increase its targeting to the spine, enhanced phosphorylation of the 
NR2b subunit of the NMDA receptor and neuronal over-excitation, which may leads to phenotypes 
like seizures or early death in the FynCA transgenic mice. We also expect phosphorylation of Tau 
at Tyr18 by Fyn may render it to be a substrate of Ser/Thr-directed kinases.   
 
Hypothesis B: Dendritic targeting of Fyn is Tau dependent [17], therefore crossing FynCA mice 
with either Tau knockout (Tau KO) or Truncated Tau (∆Tau) strain may reduce active Fyn level in 
the spine, therefore rescues the FynCA phenotype.  
 
1.3.2 AIM2: Mapping the of Tau-Fyn interaction and their dendritic localization in neurons 
 
Hypothesis A: Dendritic spine targeting of Tau dependents on specific phorphoration site. Fyn 
regulates dendritic spine targeting of Tau. 
 
Hypothesis B: Dendritic spine targeting of Fyn requires palmitoylation for its targeting to the cell 
membrane of the PSD and requires Tau to stabilize its membrane association in the spine. 
 
1.3.3 AIM3: Targeting MAPT by TALEN to study the trafficking of endogenous Tau 
  
In neurons under physiological conditions, Tau is mainly expressed in the axon, with weak 
expression in dendrites and soma. It has been hypothesized that in AD, Tau relocalizes from the 
axon to the somatodendritic part of neuron and that this process is facilitated by Aβ. Using classical 
Tau over-expression strategy however only shows a non-specific pattern that differs significantly to 
the endogenous Tau. My aim is to use genome editing tool TALEN to create a mEOS2 tagged Tau 
knock-in mice that allows us to study the Tau trafficking at the endogenous level. 
 
Hypothesis: Tau-mEOS2 neuron shows subcellular Tau expression pattern similar to WT neuron. 
 30 
 
 
 
 
 
 
 
Chapter 2. Constitutively active Fyn transgenic animals         
as a model of Fyn toxicity 
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2.1 Preface 
 
It is well known that the AD brain contains Aβ plaques and neurofibrillary tangles formed by 
hyperphosphorylated Tau. In addition to that, elevated levels of Fyn have been found and 
aggregated with Tau in a subset of neurons in the AD brain. In vivo studies crossing Fyn knockout 
mice with AD mouse models showing a rescue of Aβ toxicity suggest that Fyn is downstream of 
Aβ.  Furthermore, in vitro studies have shown that Aβ oligomers activate Fyn kinase, induce 
excitotoxicity and as a consequence cause synaptic and neuronal loss, indicating an important role 
for Fyn activation in AD pathology. Fyn interacts with and phosphorylates Tau at Tyr18, an epitope 
that has been found phosphorylated in neurofibrillary tangles. It remains unclear whether tyrosine 
phosphorylation of Tau has a role in Ser/Thr phosphorylation of Tau. In order to evaluate the 
functional consequences of Fyn activation, we generated a constitutively active mutant Y531F Fyn 
(FynCA) transgenic mouse model using the mouse Thy1.2 promoter for expression of the 
transgene. We generated FynCA transgenic mice that were found to mimic excitotoxicity, an 
increasingly recognised pathological feature of AD. Below, we describe how we analyzed the 
hyperactive phenotype of these mice. Using synapotosomal extraction, western blot analysis and 
immunohistochemistry, we evaluated Tau phosphorylation at different serine/theronine 
phosphorylation sites. This study indicated that an increased tyrosine kinase activity of Fyn has an 
affect on serine/threonine-directed phosphorylation of Tau, which may contribute to tauopathies in 
AD. 
 
 
This part of work has been published in 
 
Xia, D., & Götz, J. (2014). Premature lethality, hyperactivity, and aberrant phosphorylation in 
transgenic mice expressing a constitutively active form of Fyn. Frontiers in Molecular 
Neuroscience, 7, 40. doi:10.3389/fnmol.2014.00040 
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2.2 Abstract  
 
The kinase Fyn, the microtubule-associated protein tau and the peptide amyloid-b (Ab) constitute a 
toxic triad in Alzheimer's disease. Tau's subcellular localization is mainly regulated by 
phosphorylation whereas Fyn's localization is dictated by palmitoylation targeting it to the plasma 
membrane in a reversible manner. We have previously shown that tau is required for Fyn to be 
targeted to the dendritic spine. We had also shown that a truncated form of tau (Δtau) that 
accumulates in the cell soma is capable of trapping Fyn and preventing it from entering the spine. 
Here we determined that palmitoylation is required for Fyn's membrane and spine localization. We 
further evaluated the functional consequences of neuronal over-expression of the constitutively 
active Y531F mutant form of Fyn (FynCA) in transgenic mice. We found that the FynCA 
transgenic mice displayed a reduced weight, a massively reduced life span and a high level of 
hyperactivity. The lifespan of the FynCA mice was only slightly extended by crossing them with 
Δtau transgenic mice, possibly reflecting differences in expression patterns of the transgenes and 
high levels of transgenic FynCA compared to endogenous Fyn. Analysis of synaptosomes revealed 
that FynCA accumulated at high levels in the spine, resulting in increased levels of the NMDA 
receptor subunit NR2b phosphorylated at residue Y1472. Tau was strongly phosphorylated at the 
AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry indicating that an 
increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-
directed phosphorylation.  
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2.3 Introduction 
 
In Alzheimer's disease (AD), serine/threonine-directed phosphorylation has attracted significantly 
more attention than tyrosine-directed phosphorylation [28]. One of the reasons is that the 
microtubule-associated protein tau, a protein implicated in AD, contains 80 serines and threonines, 
many of which have been shown to be phosphorylated under disease conditions, compared to only 5 
tyrosine residues [32]. When tau transgenic mice as a model of AD are analyzed this routinely 
includes the assessment of the phosphorylation status of relevant serine and threonine residues, but 
rarely that of tyrosines. Similarly, to establish the sequence of tau-related cytoskeletal changes in 
AD, the serine/threonine-directed antibody AT8 and not a tyrosine-directed antibody has been used 
[33]. However, it is increasingly appreciated that tyrosine phosphorylation has also an important 
role in AD [34]. Of tau's five tyrosine residues, Y18 is particularly interesting because it is 
specifically phosphorylated by the tyrosine-directed kinase Fyn, a member of the Src family of non-
receptor tyrosine kinases (http://cnr.iop.kcl.ac.uk/hangerlab/tautable)  (Fig. 2.1 A). 
 
Under physiological conditions, the majority of tau is localized to the axon, whereas tau's 
'counterpart', MAP2, is mainly localized to the dendrite. However, as we have found recently, tau is 
also localized, albeit at lower levels, to the dendrite where it serves an important function that 
cannot be taken over by MAP2 [17]: Tau is required to target Fyn to the dendritic spine where it 
phosphorylates the NMDA receptor, a prerequisite for recruiting the postsynaptic density (95kD) 
protein (PSD-95) into a protein complex. This complex then mediates the excitotoxic signaling 
triggered by Ab, a peptide that aggregates and forms amyloid plaques in AD brains. In the absence 
of tau or when a form of tau is expressed that accumulates in the cell soma and is excluded from the 
dendrite (Δtau, Fig. 2.1 B), Fyn is prevented from entering the spine and thereby, Αβ cannot 
excitotoxically signal through the NMDA receptor (either directly, or indirectly) any more [17]. 
When a full-length form of tau is expressed that carries the pathogenic P301L mutation found in 
frontotemporal dementia, excitotoxic signaling is augmented because of an increased dendritic 
localization of phosphorylated mutant tau and consequently, increased levels of dendritic Fyn [35]. 
These data are supported by the finding that Αβ causes missorting of endogenous tau into the 
dendritic compartment [36]. Not surprisingly, overexpression of wild-type murine Fyn induces 
synaptic and cognitive impairments in a transgenic mouse model with Αβ accumulation[37], and 
deletion of Fyn ameliorates some of the phenotypes induced by Αβ [38]. Together, this established 
the notion of a toxic triad of the three molecules, tau, Fyn and Αβ [39], presenting Ab as the trigger, 
and tau as the bullet in AD pathogenesis [40]. 
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Fyn is a 59 kDa protein that exists as two isoforms due to alternative splicing of exon 7, with FynT 
being expressed in T-cells, and FynB in the brain and additional organs [14]. Fyn contains, in this 
order, an amino-terminal Src-homology (SH) region with acylation sites, a unique domain, an SH3 
domain (with which it interacts with PXXP motifs), an SH2 domain (with which it interacts with 
phospho-tyrosine), an SH1/kinase domain, and a carboxy-terminal regulatory tail (Fig. 2.1 A). The 
most amino-terminal glycine residue can be myristoylated, which occurs co-translationally on free 
ribosomes. In addition, Fyn's amino-terminal cysteines, C3 and C6, can be palmitoylated, and it is 
this acylation reaction that anchors the kinase to the plasma membrane. Palmitoylation in general 
enhances the hydrophobicity of proteins and contributes to their membrane association. In contrast 
to myristoylation, palmitoylation is usually reversible (because the bond between palmitic acid and 
protein is often a thioester bond) (Fig. 2.1 A). A good example of another palmitoylated protein in 
the dendritic spine is PSD-95. Interestingly, palmitoylation of Fyn seems to direct the SH4 domain 
away from the membrane, which may be important for the interaction of Fyn with target proteins 
[41]. 
 
The activity of Fyn is regulated by differential phosphorylation at multiple sites [14]. In its inactive 
state, the regulatory tyrosine at the carboxy-terminus (Y531 in mouse FynB) is phosphorylated, 
forming an intra-molecular bond with the SH2 domain of the kinase. This phosphorylation 
negatively regulates kinase activity [42]. Furthermore, the SH3 domain binds intra-molecularly to a 
linker region located between the SH2 and the kinase domain. This keeps the kinase in an inactive 
closed conformation in which both protein binding domains are occupied. Upon dephosphorylation 
of the carboxy-terminal regulatory tyrosine residue by tyrosine phosphatases, the intramolecular 
binding to the SH2 domain is abolished. Loss of SH2-dependent folding alters the conformation of 
the kinase to generate a more open form making the SH2 and SH3 domains available for 
downstream protein interactions. Furthermore, the open conformation enables an intermolecular 
auto-phosphorylation of Y420 that stabilizes the active state of the catalytic site [43]. Src kinases 
can also be stimulated by interfering with the inhibitory intra-molecular binding of SH2 and SH3 
domains which both can bind to external ligands leading to an activation of the kinase [44,45].  
 
Tau interacts with Fyn at least in two ways. Firstly, Y18 is phosphorylated by Fyn, and the 
phosphorylated motif interacts with Fyn via Fyn’s SH2 domain [46]. Secondly, Tau  
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Figure 2.1 
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Figure 2.1. Structure of Fyn, its membrane localization, and constructs used for expression 
of Fyn, tau and ∆Tau. (A) Fyn is a 59 kDa protein that contains an amino-terminal Src-
homology (SH) region with acylation sites, a unique domain, an SH3 domain (with which it 
interacts with PXXP motifs), an SH2 domain (with which it interacts with phospho-tyrosine), an 
SH1/kinase domain, and a carboxy-terminal regulatory tail. The most amino-terminal glycine 
residue can be myristoylated, which occurs co-translationally on free ribosomes. In addition, 
Fyn's amino-terminal cysteines C3 and C6 can be palmitoylated, and it is this acylation reaction 
that anchors the kinase to the plasma membrane. (B) Expression constructs for Fyn were either 
wild-type, C3S/C6S to prevent palmitoylation, or Y531F to generate a constitutively active form 
of Fyn (FynCA). Tau was expressed either as full-length (with the longest human tau isoform, 
hTau40, containing four microtubule-binding domains (MBDs) indicated in black) or a truncated 
form (∆tau) lacking the MBDs. For detection of tau and Fyn, myc, GFP and V5 were used as 
tags as indicated. 
 
contains seven PXXP motifs located in the amino-terminus (all of which are retained in the Δtau 
construct). Of these, the seventh proline-rich RTPPKSP motif has been shown to be crucial for the 
interaction with the SH3 domain of Fyn and other Src non-receptor tyrosine kinases [17,47,48]. 
Interestingly, this motif is also critical in the interaction of tau with the heterotrimeric phosphatase 
PP2A [27]. The PP2A regulatory subunit Bα binds to and dephosphorylates tau, and thereby 
regulates microtubule stability [27,49]. When Fyn is bound to the (seventh) proline-rich RTPPKSP 
motif that is conserved in both tau and MAP2, this inhibits the interaction of PP2A/Bα with 
either tau or MAP2. The corresponding synthetic RTPPKSP peptide, but not the phosphorylated 
RpTPPKSP version, competes with tau and MAP2 for binding to PP2A/Bα. This finding is 
remarkable because the down-regulation of PP2A/Bα and the deregulation of Fyn/tau interactions 
have been linked to enhanced tau phosphorylation in AD [27]. The reason why in tau knock-out 
mice, MAP2 a mainly dendritic protein cannot compensate for the absence of tau and target Fyn to 
the dendritic spine is not understood, especially as both MAP2 and tau can efficiently bind Fyn 
[27,50]. Not only tau but also MAP2 have been shown to bind to Fyn via Fyn's SH3 domain [51]. 
 
Here, we aimed to address how Fyn is localized subcellularly in vitro and what the functional 
consequences are of the transgenic overexpression of a constitutively active form of Fyn, Y531F. 
 
2.4 Material and Methods 
 
2.4.1 Mutagenesis 
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The C3S/C6S double mutation was introduced by PCR into the lentiviral vector Fyn-myc pLUV6 
that contains the human Fyn isoform 1 cDNA fused to a myc tag (Ittner et al., 2010). The resultant 
mutant construct was subcloned into the pGEM-T easy vector by TA ligation (Promega), followed 
by ApaI/SalI digestion and ligation into the pEGFP-N1 vector (Clontech) to generate a C3S/C6S 
Fyn-EGFP construct. Similarly, the Y531F mutation was cloned by PCR, with or without a myc-
tag, and subcloned via a unique XhoI site into the murine Thy1.2 expression vector pEX12 for 
subsequent neuronal expression in transgenic mice [52]. The plasmids were sequenced using the 
service of the AEGRC sequencing facility (University of Queensland). The resulting transgenic 
mice were labeled FynCA. 
 
2.4.2 Cell culture 
 
HEK293T cells were cultured in DMEM medium, supplemented with 2 mM Glutamax (Life 
Technologies) and 10% FBS (Sigma). Cells were seeded as 50% confluency in 6 cm culture dishes 
and allowed to grow for 24 h before transfection. For high efficiency transfection, lipofectamine 
LTX (Invitrogen) was used in a 2:1 ratio to DNA.  Hippocampal neurons from E18 wild-type or 
Tau knock-out [53] mouse pups were plated onto poly-D-lysine coated coverslips in a 12-well plate 
at a density of 5,000 cells/well. As a plating medium, Neurobasal medium was used, supplemented 
with 5% FBS (Hyclone), 2% B27 (Life Technologies), 2 mM Glutamax, and 50 U/mL 
penicillin/streptomycin. Neurons were switched to serum-free Neurobasal medium 24 h post-
seeding and half the medium was changed twice a week. Neurons were transfected at DIV 18 using 
lipofectamine 2000 (Invitrogen).  
 
2.4.3 Generation of transgenic mice 
 
FynCA transgenic mice were generated by pronuclear microinjection as described previously [52]. 
∆tau74 mice have been generated previously, by removing amino acids 256-441 from the longest 
human tau isoform, htau40, and expressing this truncated form of tau under control of the murine 
Thy1.2 promoter [17]. As a tau knock-out strain, mice were used that possess a GFP cassette in 
frame with the first coding exon, resulting in a fusion protein that contains the first 31 amino acids 
of tau [53]. Animal experimentation has been approved by the Animal Experimentation Committee 
of the University of Queensland. (QBI/327/11/NHMRC/ARC/BREED, QBI/027/12/ NHMRC). 
 
2.4.4 Immunohistochemistry 
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Mice were immersion fixed in 4% PFA rather than perfused because of their small size, brains 
embedded in paraffin and 7 mm sections obtained as described [54]. For antigen retrieval, the 
sections were microwaved in AR buffer (Dako Envision Flex Target Retrieval Solution low pH 
#K8005) for 15 min on low power before the buffer started to boil. The sections were then left to 
cool for 1 h in the AR buffer at RT. Blocking was done in 20% FBS, 1% BSA in TBST for 1 h at 
RT. Primary antibodies were used over night at 4 °C and secondary antibodies for 1.5 h at RT. 
Primary antibodies were Myc-Tag rabbit mAb (Cell Signalling Technologies, #71D10, used at 
1:100) and anti-Human PHF-Tau Monoclonal Antibody AT8 (Thermo Fisher, MN1020, used at 
1:400). Secondary antibodies were polyclonal goat anti-rabbit IgG biotinylated (Dako, #E0432, 
used at 1:500) and polyclonal rabbit anti-mouse IgG biotinylated  (Dako, #E0413, used at 1:500). 
The VectaStain Elite ABC Kit #PK6102 was used and Envision Flex DAB chromogen (Dako, 
#DM827) and Envision Flex Substrate Buffer (Dako, # DM823) for DAB development. 
Haematoxylin was used for counter-staining. 
 
2.4.5 Synaptosomal extraction and Western blot analysis 
 
Synaptosomes from the mouse forebrain (n=4 for the three genotypes) were prepared using a 
modified volume-adjusted protocol based on a protocol described previously [17] In brief, the tissue 
was homogenized in sucrose buffer (1ml/60mg tissue. 0.32M sucrose, 1mM NaHCO3, 1mM MgCl2, 
0.5mM CaCl2) using a tissue homogenizer. Brain homogenate was centrifuged at 1,400 g for 10 
min and cleared by centrifugation at 720 g for 10 min. 200 mL of supernatant was collected as 
whole brain lysate and the pellet containing cell debris and nuclei was discarded. The remaining 
supernatants were then centrifuged at 13,800 g for 10 min to obtain the crude synaptosomes in the 
pellet (P). The pellet was resuspended in 200 ml Sucrose Buffer, layered over 1.8 mL pre-cooled 
5% Ficoll and centrifuged at 45,000 g for 45 min. The supernatant was then removed carefully and 
the pellet resuspended in 200 mL pre-cooled 5% Ficoll, which was then layered over 1.8 mL pre-
cooled 13% Ficoll and centrifuged at 45,000 g for 45 min. A milky interface containing the 
synaptosomes was recovered, topped-up with 5% Ficoll to 2 mL and centrifuged at 45,000 g for 25 
min to pellet the synaptosomes. Purified synaptosomes were further extracted sequentially with 
buffers of increasing stringency: pH6 (40 mM Tris-HCl, 2% Triton X-100, 0.5 mM CaCl2); pH8 
(20 mM Tris-HCl, 1% Triton X-100); and SDS (5% SDS). The SDS buffer extract contains strongly 
PSD-associated proteins. This fraction was named 'PSD'. All centrifugations were carried out at 4 
°C. For Western blot analysis, the following primary antibodies were used: total Tau (Dako, 
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polyclonal, 1:5,000), Fyn (Fyn15; monoclonal, Santa Cruz, 1:500), PSD-95 (Millipore, 1:2,000), 
GAPDH (polyclonal, Millipore, 1:5,000), NR2b (polyclonal, Millipore, 1:1,000), pTyr1472- NR2b 
(polyclonal, Sigma, 1:1,000), Myc-tag (71D10, rabbit monoclonal, 1:2,000), AT8 (phospho-tau, 
pSer202 + pThr205, monoclonal, Thermo, 1:1,000), 12E8 (phospho-tau pSer262 (+ pS356)), 
polyclonal, Thermo, 1:4,000), HT7 (human Tau, monoclonal, Thermo, 1:2,000) and Actin 
(monoclonal, Millipore, clone C4, monoclonal, 1:5,000). 
 
2.5 Results 
 
2.5.1 Palmitoylation of Fyn is required for spine localization 
 
Fyn contains two cysteines (C3 and C6) that are acetylated in a palmitoylation reaction. To 
determine the role of these residues in subcellular localization we mutated the palmitoylation signal 
by replacing the two cysteines by serines as described [55], and equipped Fyn with a GFP tag. 
When transfected into HEK293 cells, this revealed a membrane association for wild-type Fyn (Fig. 
2.2 A). Fyn(C3S/C6S), in contrast, was excluded from the plasma membrane and accumulated 
intracellularly in endosomes [56] (Fig. 2.2 B). We next determined the subcellular localization in 
primary hippocampal cultures obtained from wild-type mouse embryos. After 21 days (DIV21) in 
culture, the neurons displayed a myriad of spines. We co-transfected the cultures with RFP and 
either Fyn-GFP or Fyn(C3S/C6S)-GFP and found that wild-type Fyn was localized to spines (Fig. 
2.2 C-E) whereas Fyn(C3S/C6S)-GFP was excluded from entering the spines (Fig. 2.2 F-H). 
Together this reveals that palmitoylation and hence, membrane association, is required for the 
localization of Fyn into dendritic spines. 
 
We have previously shown that Δtau in Δtau74 transgenic mice is localized to the cell body, but 
excluded from the dendritic compartment [17]. This finding was also supported biochemically, by 
analyzing synaptosomal preparations and comparing Δtau localization with that of full-length tau. 
To determine whether Δtau is also excluded from the dendritic compartment and in particular, 
spines, in primary neuronal cultures, we transfected both full-length tau equipped with  
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Figure 2.2. Palmitoylation and hence, membrane association, is required for the 
localization of Fyn into dendritic spines. Transfection of Fyn expression constructs in HEK293 
cells (A, B) and primary hippocampal cultures (C-H) reveals that wild-type Fyn associates with 
the plasma membrane in HEK293 cells (A), whereas mutating Fyn's two cysteines (C3/C6) that 
are acetylated in a palmitoylation reaction to cysteines causes Fyn's accumulation intracellularly 
in endosomes (B). In the neuronal cultures, wild-type Fyn is localized to spines (C-E) whereas 
Fyn(C3S/C6S)-GFP is excluded from entering the spines (F-H). RFP (D, G) was used to 
visualize all neuronal structures including the spines. Scale bar: 10 mm (A, B); 20 mm (C-H)  
 
a V5 tag (Tau-V5) together with RFP, and Δtau-V5 together with RFP, respectively, using primary 
neuronal cultures derived from tau knock-out mice. This showed that full-length tau is distributed 
throughout the neuron, but excluded from the spines (Fig. 2.3 A-C). In contrast, Δtau was 
dramatically reduced from the dendritic compartment and levels were found to be below detection 
levels past the secondary branch-point (as indicated by the arrows) (Fig. 2.3 D-E). We next 
determined whether expression of Δtau would affect Fyn localization, by co-transfecting wild-type 
neurons with Fyn-EGFP, RFP and Δtau-V5 (Fig. 2.3 G-K). We found that different from Δtau74 
mice where transgenic over-expression of Δtau (or knocking-out endogenous tau) prevented 
endogenous Fyn from entering the spines [17], transfecting Δtau into primary neurons was not 
capable of preventing transfected Fyn (Fyn-EGFP) from entering the spine, possibly reflecting 
excessive expression of Fyn in over-expression system. 
 
2.5.2 Mice with a constitutive expression of Fyn are characterized by reduced weight, 
hyperactivity and premature death 
 
In brain, Fyn is expressed in both neurons and glial cells, and in both cell-types, tau has an 
important function in regulating Fyn [17,57]. To establish a mouse model with constitutive 
expression of Fyn in neurons, we introduced the Y531F mutation into the human Fyn cDNA and 
cloned this 'FynCA' cDNA into the mThy1.2 expression vector for neuronal expression, generating 
constructs that either contained or did not contain the myc tag for subsequent detection (Fig. 2.1 B). 
We generated a series of transgenic founders by pronuclear injection of C57BL/6 x DBA/2 oocytes: 
four (#11, 15, 16 and 17) without a myc tag, and 10 (#4, 12, 13, 14, 20, 22, 24, 35, 55 and 58) with 
a tag. We screened the offspring obtained from these FynCA founder animals by Western blotting 
and found that whenever the transgene-positive offspring died early (what happened around three 
weeks of age), the transgene was expressed at detectable levels, whereas when the mice did not die  
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Figure 2.3. Subcellular localisation of Fyn and ∆tau. Transfection of tau knock-out primary 
neuronal cultures with a full-length tau construct equipped with a V5 tag (Tau-V5) (A) together 
with RFP (B) shows distribution of full-length tau throughout the neuron, but spines are 
excluded. (Merged image: C). Transfection of Δtau-V5 (D) together with RFP (E) reveals that 
Δtau is dramatically reduced from the dendritic compartment, and that levels are below detection 
past the secondary branch-point (as indicated by the arrows) (Merged image: F). When Fyn-
EGFP (G) was over-expressed together with Δtau-V5 (H) and RFP (I) in wild-type primary 
neurons, different from Δtau74 mice where transgenic over-expression of Δtau prevents 
endogenous Fyn from entering the spines, transfecting Δtau into primary neurons does not 
prevent transfected Fyn from entering the spine, possibly reflecting differences in the expression 
levels (Merged image: K). Scale bar: 100 mm (A-K) 
 
at an early age the offspring of that particular founder did not express the transgene at detectable 
levels (Fig. 2.4 A). We specifically identified founders #14, 35 and 55 as generating offspring 
characterized by early lethality. The transgene-positive offspring derived from these lines was 
significantly smaller, as shown for #55 offspring (Fig. 2.4 B), and showed less weight gain than the 
non-transgenic littermates such that by 2-3 weeks of age they would only have half the weight of 
non-transgenic littermates (Fig. 2.4 C). The transgenic mice displayed persistent tremor and lack of 
coordination while moving, as well as pronounced hyperactivity and an altered locomotion behavior 
(Please check http://journal.frontiersin.org/article/10.3389/fnmol.2014.00040/full online for 
supplementary movie, shown at 18 days of age). More specifically, when separated from the litter 
they would start running in circles in the cage for hours, and this could only be halted when the 
transgenic mice were put back to the litter. Interestingly, only a slight separation from the litter was 
sufficient to re-instigate this type of behavior, suggesting high levels of anxiety in FynCA mice. To 
complement the movie, we recorded the path of four mice each aged 18 days of age for 1 min, after 
the mice had been kept isolated in a box for 1 hour (Fig. 2.4 D). 
 
2.5.3 Partial rescue of FynCA mice by crossing onto a ∆tau background 
 
We next analyzed the offspring of the FynCA founder animals both by immuno-histochemistry 
(Fig. 2.5) and Western blotting (Fig. 2.6) using a monoclonal anti-Fyn antibody. The latter revealed 
a strong expression of Fyn (59 kDa) in mouse brains derived from the FynCA founders #14, 35 and 
55. As shown for offspring of founder #55, levels of Fyn in FynCA transgenic mice were 
approximately six-fold higher than those for endogenous murine Fyn in wild-type mice (Fig. 2.6 A). 
The affinity of the antibody for human and murine Fyn is expected not to differ because of a 100%  
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Figure 2.4. FynCA mice are characterized by reduced weight, early mortality and 
hyperactivity. Transgene-positive offspring derived from FynCA founders #14, 35 and 55 is 
characterized by early lethality (A). Crossing FynCA mice with Δtau mice results in a slight 
extension of the life span of the FynCA mice. The transgene-positive offspring derived from 
these lines tends to be smaller as shown for #55 offspring (B), and to show less weight gain than 
the non-transgenic littermates such that by 2-3 weeks of age they weigh only half of their non-
transgenic littermates (Student's t-test, P < 0.0001) (C). Tracking of four FynCA transgenic mice 
(top) and four non-transgenic littermates (bottom) at 18 days of age. The FynCA mice run in 
circles and keep this hyperactivity up for hours unless being put back to their litter (D). 
 
homology of the epitope used for immunization as well as flanking sequences. We next determined 
the expression pattern of FynCA in #55 offspring by immunohistochemistry using a rabbit anti-myc 
antibody to visualize FynCA expression. We found that FynCA was widely expressed in FynCA 
transgenic brain (Fig. 2.5 A), using non-transgenic littermates as controls (Fig. 2.5 B). Prominent 
expression of the FynCA transgene was found in neurites and fiber tracts as shown for the 
hippocampus and the fimbria fornix, but the FynCA transgenic protein was also found 
accumulating in the cell bodies e.g. of large motor neurons in the brain stem and in nuclei such as 
the pontine nucleus. As tau is a substrate of Fyn we aimed to assess its phosphorylation in the 
FynCA mice. The phospho-Y18-tau-specific antibody 9G3 could not be employed because it is 
human tau-specific and does not detect murine tau phosphorylated at Y18 [47]. We therefore aimed 
to determine whether Ser/Thr-directed phosphorylation is increased in the presence of constitutively 
active Fyn. In human tau transgenic mice phosphorylation of Ser/Thr-epitopes of tau only occurs as 
the mice become older. We nonetheless analyzed two week-old FynCA mice using the phosphotau-
specific antibody AT8 (Fig. 2.5 C), using non-transgenic littermates as controls (Fig. 2.5 D). We 
found that the mice were strongly phosphorylated at the AT8 epitope in fiber tracts as shown for the 
hippocampus, and pronounced AT8-immunoreactivity was also seen in cell bodies in several brain 
areas. 
 
To determine whether expression of Δtau would ameliorate the FynCA pathology at least to a 
degree that would allow us to establish FynCA lines from the founder animals, we bred the FynCA 
founders with Δtau74 mice. Δtau is widely expressed in the brains of Δtau74-transgenic mice as 
revealed with the human tau-specific antibody HT7, whereas no expression is found in non-
transgenic littermate controls [17]. Based on the co-transfection experiments in primary neurons 
(Fig. 2.3 G-K) and because of differences in expression patterns between Δtau in Δtau74 mice and  
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Figure 2.5. Fyn expression in FynCA mice and tau phosphorylation. A myc-specific 
antibody was used to reveal Fyn expression in FynCA-transgenic mice (A), using non-transgenic 
littermates as controls (B). Phosphorylation of endogenous tau was revealed using the 
Ser202/Thr205-specific antibody AT8, analyzing FynCA-transgenic mice (C) and non-
transgenic littermate controls (D).  
 
FynCA in FynCA55 mice (which is in part due to different integration sites of the transgenes) (Fig. 
2.5), we expected only a subtle effect on survival. This is in fact what we observed because the 
rescue conferred by Δtau on the mortality of the FynCA mice was very subtle (Fig. 2.4 A).  
 
2.5.4 Increased phosphorylation of NR2b and tau in FynCA mice 
 
We next obtained synaptosomal fractions adopting a previously established protocol [17]. Different 
from what we had done previously [17], we used whole forebrains rather than pooled hippocampi. 
We sequentially extracted synaptosomes (n=4 per genotype) from wild-type, FynCA and FynCA x 
Δtau (Tau+/-) mice and analyzed the PSD fraction containing the postsynaptic density (PSD) for 
levels of Fyn, PSD-95, the NMDA receptor subunit 2b (NR2b), NR2b phosphorylated at Y1472, 
tau, and tau phosphorylated at the AT8 epitope S202/T205 and at the 12E8 epitope S262(/S356), 
using actin and PSD95 for normalization (Fig. 2.6 A,B). We also obtained total brain extracts, and 
as mentioned above, found that levels of transgenic FynCA expression were approximately six-fold 
higher than endogenous murine Fyn (Fig. 2.6 A).  
 
When we analyzed the PSD fraction we detected massively increased levels of Fyn in FynCA 
compared with wild-type mice. When FynCA mice co-expressed Δtau, Fyn levels in the PSD 
fraction were not reduced, suggesting that either high levels of Fyn override the inhibition by Δtau 
in targeting Fyn to the spine (as observed for normal Fyn levels in Δtau74 mice) or non-overlapping 
expression patterns, or both. We found high levels of tau in the PSD fraction. Interestingly, whereas 
in total extracts obtained from FynCA mice, tau was massively phosphorylated at the AT8 epitope 
(tau phosphorylated at S202/ S205) (reflecting the histological data), we failed to detect tau 
phosphorylated at AT8 in the PSD fraction. This would suggest that if tau in the FynCA mice were 
phosphorylated at the AT8 epitope, levels in the spines would be very low. Interestingly, when 
FynCA mice were crossed onto a Δtau background, in total brain extracts, tau phosphorylation at 
the AT8 epitope was strongly reduced. Note: Δtau itself is not phosphorylated at the AT8 epitope, 
which is in line with previous observations showing that Δtau is not highly phosphorylated [17,57].  
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Figure 2.6. Western blot of total brain extract and synaptosomal fractions. We compared 
wild-type mice (1,2), FynCA mice (3,4) and FynCA mice crossed onto a Δtau background (5,6). 
(A) Total extracts and synaptosomal PSD (SDS) fractions (B) were analyzed with antibodies for 
GAPDH, actin, Fyn (short and long exposure), Myc, PSD-95, NR2b, NR2b phosphorylated at 
Y1472, total tau, human tau (HT7) detecting Δtau, and phospho-tau (AT8, 12E8).  
 
In agreement with these previous data, Δtau is not targeted to the PSD (Fig. 2.6 B). We also 
assessed tau phosphorylation at the 12E8 epitope (tau phosphorylated at S262 and possibly S356) 
and found that for the FynCA mice, 12E8 phosphorylation in the PSD fraction was increased 
compared with the fraction obtained from non-transgenic littermate controls. This increase was 
slight and not found in mice co-expressing FynCA and Δtau.  
 
We further assessed NR2b phosphorylation and found that Y1472 phosphorylation was 
approximately four-fold increased in total extracts and in the PSD fraction obtained from FynCA 
compared with wild-type mice, and that levels were also increased when Δtau was co-expressed 
with FynCA. 
 
2.6 Discussion  
 
Using two cellular systems we firstly showed that the palmitoylation signal is critical for the 
subcellular localization of the kinase Fyn: Mutating the two critical amino-terminal cysteine 
residues into serines abrogates localization of Fyn to the plasma membrane in HEK293 cells, and to 
dendritic spines in primary neuronal cultures. By mutating Y531 of Fyn to phenylalanine, we 
generated mice that express a constitutively active form of Fyn in neurons. These mice are 
characterized by early lethality around the age of weaning, a massively reduced weight and 
hyperactivity. We are also presenting preliminary evidence that the constitutively active Fyn causes 
phosphorylation of endogenous murine tau at serine and threonine residues, as shown for the AT8 
phospho-epitope of tau by both immunohistochemistry and Western blot analysis. Interestingly, tau 
in the spine seemed either not to be phosphorylated at AT8 at all or at least levels must be very low 
as we failed to detect AT8 phosphorylation in the 'PSD blot' that was processed together with the 
'total blot'. 
 
Fyn is a kinase that has been proposed to act as a signal integration hub that is involved in a vast 
number of cellular programs [58]. In a pathological context such as AD, Fyn has been shown to 
integrate signals that ultimately lead to neuronal demise. Fyn mediates the downstream toxicity of 
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Αβ by over-activating cellular receptors such as the NMDA receptor either directly or indirectly 
[17]. An additional role has been presented for the prion protein, PrPc. It has been shown that Aβ-
induced dendritic spine loss requires both PrPc and Fyn, and that in mice lacking PrPc, human 
familial AD transgene-induced convulsive seizures do not occur [59]. More recently, the 
metabotropic glutamate receptor 5 (mGluR5) was shown to function as a co-receptor of PrPc 
[60]. Soluble Aβ was found to bind to PrPc at dendritic spines where PrPc forms a complex with 
Fyn, resulting in the activation of Fyn and subsequent Y18 phosphorylation, as shown with 
antibody anti-pY18 [61]. However, how tau and Fyn are targeted to the dendritic spine is not 
understood. Two scenarios have been discussed previously [61]: (i) Either Fyn is not bound to tau 
before entering the spine and activated Fyn then causes the phosphorylation of tau at Y18 resulting 
in its aberrant accumulation at the postsynaptic density (PSD). It is possible that at this stage 
phosphorylated Fyn might be bound to phosphorylated Tau binding to the SH3 domain of PSD-95, 
where it is ideally located to modulate NMDA receptor subunits such as NR2b at residue Y1472 
[17] [17]. (We found that FynCA is localized to the spine where it phosphorylates NR2b at Y1472.) 
(ii) The alternative scenario is that in the dendrite, Fyn is already bound to tau, which then 
translocates to the PSD to interact with PSD-95. There, another tyrosine kinase, Pyk2 [62]  [62], 
could potentially activate Fyn and cause phosphorylation of tau at Y18. We found that increased 
levels of activated Fyn causes increased levels of phosphorylated Tau in the FynCA mice as shown 
for the AT8 epitope, although no increased phosphorylation was found for the spines. A time-
resolved model for how Αβ via Fyn ultimately causes neuronal demise has been presented by Jannic 
Boehm, integrating the effects of Αβ on Fyn and STEP, a Fyn-phosphatase that eventually 
inactivates Fyn [34]. 
 
Co-expressing Δtau and FynCA did not result in reduced levels of Fyn in the synaptosomal 
compartment. We had previously shown that transgenic expression of Dtau, which accumulates in 
the soma and is prevented from entering the dendrites, traps (endogenous) Fyn in the cell body and 
prevents it also from entering the spines [17]. When FynCA is massively over-expressed, levels of 
Dtau seem not to be sufficient to prevent Fyn from entering the spines suggesting that manipulation 
of tau levels for therapeutic intervention may not be beneficial when Fyn is highly activated and/or 
its levels are increased, as may be the case under disease conditions. On the other hand it has been 
reported for AD brains by quantitative immunoblotting that Fyn levels were increased in the 
insoluble fraction and decreased in the soluble fraction. Soluble Fyn levels were directly correlated 
with cognitive scores inversely correlated with tau-containing neurofibrillary tangle counts in the 
frontal cortex [63]. 
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In spines it has been shown that hyperphosphorylated tau abnormally accumulates [64]. We have 
shown previously that in the presence of elevated levels of (phosphorylated) human tau, Αβ toxicity 
is exaggerated, most likely because, under these conditions, more Fyn enters the spine [17,35]. In 
the presence of oligomeric Aβ tau not only changes its phosphorylation status but also alters its 
subcellular localization [36,65]. A role for tau phosphorylation specifically at the 12E8 epitope 
Ser262/Ser356 has been shown to be required for Ab-mediated spine loss mediated via the CaMK2-
AMPK signaling pathway [66]. We found in the present study that increased Fyn activity and levels 
in the spine do not necessarily result in increased phosphorylation, at least as shown for the AT8 
epitope. This is different for the 12E8 phospho-epitope of tau, which reveals a slight increase in the 
FynCA PSD fraction compared to both non-transgenic littermate controls and mice co-expressing 
FynCA and Δtau. Further work needs to go into how Fyn regulates tau phosphorylation and what 
the requirements are for dendritic and spine localization of distinct phospho-pools of tau. Whether 
the results of our study were different if we were to analyze hippocampal fractions remains to be 
determined. 
 
Earlier studies have been looking into transgenic mice that expressed FynB Y531F controlled by a 
CaMKII/SV40 expression vector [67]. The mice presented with higher seizure susceptibility. They 
also showed enhanced tyrosine phosphorylation of the NR2b subunit of the NMDA receptor. This 
was demonstrated by immuno-precipitating the NR2b subunit from the PSD fraction, running a blot 
and probing it with a phospho-tyrosine-specific antibody. We confirmed this finding by probing the 
PSD fraction directly with an NR2b phospho-Y1472-specific antibody. Further work by Kojima 
and colleagues showed that an impairment of long-term potentiation in the absence of Fyn could be 
rescued by reintroducing FynB under control of the CamKII promoter [68]. When the constitutively 
active form of Fyn, Y528F was expressed in the epidermis using the keratin 14 promoter for 
expression [69], 10% of homozygous mice died before weaning. Otherwise the mice were normal in 
size, and as they aged they developed spontaneous skin tumors. Together with our findings this 
reveals an important role for Fyn in peripheral organs and the brain. 
 
Further work is required to determine how Fyn and tau are transported into the spine, which 
posttranslational modifications govern this process and which kinases are activated by the tyrosine 
kinase Fyn in order to cause serine/threonine-directed phosphorylation of substrates such as tau.  
 
 
 52 
 
 
 
 
 
 
 
Chapter 3. Tau targets to dendritic spines                                   
- a mutagenesis study 
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3.1 Preface 
 
Tau is a microtubule binding protein that under physiological conditions mainly localizes to the 
axon, however, the protein has also been found to be weakly expressed in the dendrite and spines, 
where its levels are increased by different stimuli including synaptic activation or Aβ treatment. 
Previous research from different laboratories has shown that sorting of Tau into the dendritic spine 
is phosphorylation-dependent. In AD transgenic mice, overexpression of the human APP Swedish 
double mutation (APP23) or the human FTD mutant P301L tau mutation (pR5) resulted in elevated 
levels of hyper-phosphorylated Tau in dendritic spines; however, a role for distinct phosphorylation 
sites had not been established. Tau interacts with the Src kinase Fyn and is required for Fyn to 
target to dendritic spines. It remains to be determined whether Fyn also contributes to the dendritic 
spine targeting of Tau, considering that Fyn phosphorylates Tau at the tyrosine 18 residue. Tau is 
phosphorylated at Tyr18 in AD brains, with phosphorylation levels correlating with disease 
progression. It is quite possible that tyrosine phosphorylation of Tau may regulate the 
phosphorylation of Tau at serine and threonine residues, such as the AT8 and 12E8 epitopes, as we 
have found in the above FynCA transgenic animal study.  
 
In order to determine which domains and phosphorylation sites are required for dendritic spine 
targeting of Tau, and whether Fyn is also required in this process, we performed an extensive 
mutagenesis study by overexpressing different Tau truncation or phospho-mutants in cultured 
neurons obtained from wild-type and Fyn knockout animals. We then used immunocytochemistry 
and calculated the spinal targeting ratio of different Tau mutants. Our results revealed that 
pseudophosphorylation of specific sites is sufficient to target Tau into the spine and that targeting of 
overexpressed mutant Tau into the spine is Fyn-independent. 
 
This part of work has been published in  
 
Xia D., Li C., & Götz J. (2015). Pseudophosphorylation of Tau at distinct epitopes or the presence 
of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines -
Biochimica Biophysica Acta (BBA) - Molecular Basis of Disease, 1852(5), 913–924.  
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3.2 Abstract  
 
Alzheimer's disease is characterized by the accumulation of amyloid-β (Aβ) and Tau in brain. In 
mature neurons, Tau is concentrated in the axon and found at lower levels in the dendrite where it is 
required for targeting Fyn to the spines. Here, Fyn mediates Aβ toxicity which is vastly abrogated 
when Tau is either deleted or a truncated form of Tau (Tau1-255) is co-expressed. Interestingly, 
MAP2, a microtubule-binding protein with mainly dendritic localization that shares Fyn-binding 
motifs with Tau, does not mediate Aβ's synaptic toxicity in the absence of Tau. Here we show in 
hippocampal neurons that endogenous Tau enters the entire spine, albeit at low levels, whereas 
MAP2 only enters its neck or is restricted to the dendritic shaft. Based on an extensive mutagenesis 
study, we also reveal that spine localization of Tau is facilitated by deletion of the microtubule-
binding repeat domain. When distinct phosphorylation sites (AT180-T231/S235, 12E8-S262/S356, 
PHF1-S396/S404) were pseudophosphorylated (with glutamic acid, using alanine replacements as 
controls), Tau targeting to spines was markedly increased, whereas pseudophosphorylation of the 
late phospho-epitope S422 had no effect. In determining the role physiological Fyn has in spine 
localization of Tau, we found that neither were endogenous Tau levels reduced in Fyn knockout 
compared with wild-type synaptosomal brain fractions, nor was spine localization of over-expressed 
pseudophosphorylated or P301L Tau. This demonstrates that, although Fyn targeting to the spine is 
Tau-dependent, elevated levels of phosphorylated Tau or P301L Tau can enter the spine in a Fyn-
independent manner.  
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3.3 Introduction  
 
Alzheimer’s disease (AD), as the most common form of dementia [70], is characterized by two 
hallmark lesions, plaques that contain the amyloid-β (Aβ) peptide as their major constituent, and 
neurofibrillary tangles that are mainly composed of heavily phosphorylated forms of the 
microtubule-associated protein (MAP) Tau [71]. Tau is an unusual protein because it contains 80 
serine and threonine residues as well as 5 tyrosine residues [32]. More than a dozen of these sites 
are already phosphorylated under physiological conditions, although to a varying degree. In AD, 
Tau is hyperphosphorylated, which means that some of these residues display increased 
phosphorylation, whereas others are de novo phosphorylated [72]. To date, most research has 
focused on serine/threonine rather than tyrosine-directed phosphorylation, assisted by the early 
availability of antibodies that recognize distinct phosphorylated serine and threonine epitopes on 
Tau.  
 
Tau is up-regulated during neuronal development. The fetal form of Tau is initially distributed 
evenly in the cell body and neurites (Fig. 3.1 A-H). When axons emerge and neurons become 
polarized, Tau becomes enriched in axons. In mammalian neurons, this axonal sorting takes place 
within 1-2 weeks [73]. In mature neurons, under physiological conditions, the majority of Tau is 
localized to the axon, whereas MAP2, another member of the MAP family, is mainly localized to 
the dendrite. However, as we have reported recently for brains of adult mice, Tau is also localized, 
albeit at lower levels, to the dendrite where it serves an important function that cannot be fulfilled 
by MAP2 [17]. Here, Tau is required for the targeting of the Src kinase Fyn to dendritic spines 
where Fyn phosphorylates the NMDA receptor, a prerequisite for recruiting the postsynaptic 
density (95kD) protein (PSD95) into a protein complex. This complex then mediates the excitotoxic 
signaling that is triggered by Aβ, the preferential binding site of which is at the synapse [74]. 
However, Tau also has a physiological role in the spine where it is thought to participate in spine 
edification [75]. Furthermore, synaptic activation has been shown to induce the translocation of Tau 
to the synaptic compartment, where it interacts with filamentous actin [76]. The same study also 
demonstrated that a short exposure of cortical cultures to oligomeric Aβ induces mislocalization of 
Tau into the spines under resting conditions, and abrogates its subsequent activity-dependent 
synaptic translocation. Together, these findings suggest differences in synaptic Tau dynamics 
depending on whether it is physiologically or pathologically phosphorylated.  
 
In the absence of Tau or when a form of Tau is expressed that accumulates in the cell soma and is 
excluded from the dendrite (such as the 255 amino acid-long ΔTau that contains the projection 
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domain but lacks the microtubule-binding repeats; MBRs), Fyn is prevented from entering the 
spines, as a result of which Aβ can neither directly nor indirectly signal through the excitotoxical 
NMDA receptor [17]. This finding has resulted in several models that aim to explain how Aβ, Tau 
and Fyn interact in the postsynapse to cause damage to neurons [35,77].  
 
Fyn contains an amino-terminal Src-homology (SH) region with acylation sites, a unique domain, 
an SH3 domain (with which it interacts with PXXP motifs), an SH2 domain (with which it interacts 
with phospho-tyrosine residues), an SH1/kinase domain, and a carboxy-terminal regulatory tail 
[14]. Tau interacts with Fyn at least in two ways. Firstly, the Y18 residue of Tau is phosphorylated 
by Fyn, with the phosphorylated motif interacting with Fyn via the latter's SH2 domain [46]. 
Secondly, Tau contains seven PXXP motifs that are localized amino-terminal of the microtubule-
binding domain and are arranged consecutively. Of these motifs, the seventh has been found to be 
crucial for the interaction with the SH3 domain of Fyn and other Src non-receptor tyrosine kinases 
[17,47,48]. Interestingly, this motif is also critical for the interaction of Tau with the protein 
phosphatase PP2A [27]. Why the mainly dendritic protein MAP2 cannot compensate for the 
absence of Tau in Tau knockout (TauKO) mice and target Fyn to dendritic spines is not understood, 
particularly as both MAP2 and Tau efficiently bind Fyn [27,50,51].  
 
In recent years, several groups have investigated the role of Tau at the postsynapse [77]. Aβ was 
found to change the phosphorylation status of Tau and alter its subcellular localization [36,78], with 
a specific role reported for the S262 epitope of Tau (a site recognized by the antibody 12E8) [66]. 
How the Tau/Fyn-interaction is regulated and the relative role of the phospho-Y18/SH2 and 
PXXP/SH3 interactions are not fully understood.  It has been shown that tyrosine phosphorylation 
of Tau has a role in disease progression [47], possibly by triggering down-stream phosphorylation 
of serine and threonine residues. In the present study, we expressed truncated, 
pseudophosphorylated and alanine-mutated (non-phosphorylatable) forms of Tau in primary 
hippocampal cultures from C57BL/6 wild-type and Fyn knockout (FynKO) mice to determine what 
dictates the localization of Tau to the spine.  
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Figure 3.1 
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Figure 3.1. Tau and MAP2 segregate with advanced primary neuron development; when 
spines have formed, endogenous MAP2 and Tau are both localized to dendrites, but 
whereas Tau enters the spines, MAP2 only enters the spine neck. (A-H) With advanced time 
in culture, primary hippocampal neurons from wild-type mice undergo a process of 
compartmentalization of Tau and MAP2 (DIV1.5, A-C,G; DIV5, D-F,H; close-ups of cell 
bodies in G,H). (I-M) At DIV20, Tau is more concentrated in axons, whereas MAP2 is 
concentrated in dendrites. Using actin to visualize spines (K), localization reveals that unlike 
Tau, that enters the head of spines (indicated by arrows) (L), MAP2 only enters the neck (M). 
Merged image (N) with Tau (in green), MAP2 (in red) and actin (in blue). DIV, days in vitro. 
Scale bar: A-F (25 µm), I-M (2 µm). 
 
3.4 Materials and methods 
 
3.4.1 Mouse strains and animal ethics 
 
The mouse strains used in this study included C57BL/6, TauKO  [53], FynKO  [79]and Tau transgenic 
pR5 mice that express the P301L mutation found in familial cases of frontotemporal dementia 
(FTD) [54]. Animal experimentation was approved by the Animal Ethics Committee of the 
University of Queensland (approval number QBI/027/12/NHMRC). 
 
3.4.2 Primary culture  
 
Hippocampal neurons from embryonic day (E) 18 wild-type or FynKO mouse embryos were plated 
onto poly-D-lysine coated coverslips in a 12 well plate at a density of 5,000 cells/well [80]. The 
plating medium was based on Neurobasal medium (Invitrogen), supplemented with 5% fetal bovine 
serum (Hyclone), 2% B27, 2 mM Glutamax (Invitrogen) and 50 U/mL penicillin/ streptomycin 
(Invitrogen). This was changed to serum-free Neurobasal medium 24 h post-seeding and half the 
medium was changed twice a week. Neurons were transfected at 18 days in vitro (DIV18) using 
Lipofectamine 2000 (Invitrogen).. 
 
3.4.3 Mutagenesis and molecular cloning 
 
Tau mutant constructs were generated by site-directed mutagenesis, using a pENTR donor vector 
containing full-length human 2N4R Tau (hTau40, 441aa) as a template. To introduce a V5 tag at the 
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carboxy-terminus, Gateway cloning was used, and the Tau cassette was transferred from the 
pENTR donor vectors into the pcDNA6.2/V5-DEST vector, using LR clonase (Invitrogen).  The 
following expression vectors were generated (Fig. 3.2): ∆Tau (∆256-441), ∆PXXP (∆176-242); 
∆MTB (∆256-367); P301L, Y18A; mutants of the AT180 epitope (T231A/S235A and 
T231E/S235E); mutants of the 12E8 epitope (S262A/S356A and S262E/S356E); mutants of the 
PHF1 epitope (S396A/S404A and S396E/S404E); and mutants of the serine 422 epitope (S422A 
and S422E). In addition, an additional myc-tagged construct was generated for AT180A 
(T231A/S235A). For an overview of the Tau phosphorylation sites used in this study, see [81]. The 
MAP2c-EGFP plasmid was kindly provided by Dr. Estelle Sontag (University of Newcastle, 
Australia). We thank Dr. Xiaobing Yuan (Department of Neurobiology and Anatomy, Drexel 
University College of Medicine, USA) for the EGFP-α-tubulin plasmid. 
3.4.4 Immunocytochemistry and imaging analysis  
 
Primary hippocampal neurons were transfected at DIV18. A red fluorescent protein, (tagRFP, in 
short: RFP; Evogen) expression vector was co-transfected to fully visualize the structures of 
neurons, i.e. including the spines. 48 h after the transfection, cells were washed once with PBS, 
fixed with 4% paraformaldehyde/4% sucrose for 10 min, permeabilized with 0.2% Triton X-100 for 
10 min, then blocked for 1 h in 10% goat serum, followed by incubation of primary antibodies 
overnight at 4 °C.  To visualize endogenous Tau and MAP2, images were also taken at DIV1.5, 
DIV5 and DIV21. Primary antibodies were mouse anti-myc (Sigma, 1:500), rabbit anti-V5 (Sigma, 
1:500), rabbit anti-MAP2 (Millipore; 1:500), mouse anti-Tau5 (Millipore, 1:500), and mouse anti-
PSD95 (Millipore, 1:500). Secondary antibodies were Alexa Fluor (488, 555, 647)-labeled goat 
anti-mouse and goat anti-rabbit IgG antibodies (Invitrogen). We further used Alexa Fluor647-
labeled phalloidin (Invitrogen) to detect actin. Fluorescence images were taken with a 20 or 60X 
objective on a Zeiss LSM710 laser scanning confocal microscope. Super-resolution structured 
illumination microscopy (SIM) images were taken with a 60X objective on a Zeiss ELYRA PS.1 
SIM/STORM microscope 
3.4.5 Synaptosomal preparations and western blot analysis 
 
Synaptosomes were prepared from dissected forebrains (n=4 for the each genotypes) using a 
modified volume-adjusted method based on a previously published protocol [17]. In brief, brain 
tissue was homogenized in sucrose buffer (1 ml/60 mg tissue, 0.32 M sucrose, 1 mM NaHCO3, 1 
mM MgCl2, 0.5 mM CaCl2) using a dounce homogenizer (800 rpm, 10 strokes). The  
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Figure 3.2. Tau mutation/truncation constructs. Tau constructs generated to determine the 
role of critical epitopes in the localization of Tau to spines. The longest human Tau isoform, 
hTau40, was used as a template. This contains four microtubule-binding domains (MBRs) that 
are indicated in black. Fyn has been shown to bind Tau via its SH3 domain and, in a 
phosphorylation-dependent manner, via its SH2 domain. All Tau constructs contain a short V5-
tag. 
 
brain homogenate was centrifuged at 1,400 g for 10 min. 200 ml of the supernatant was collected as 
the 'whole brain lysate' and the pellet containing cell debris and nuclei was discarded. The 
remaining supernatant was then centrifuged at 14,000 g for 20 min to obtain the crude synaptosomal 
fraction in the pellet. The pellet was then re-suspended in 2 ml sucrose buffer, layered over a 
discontinuous Ficoll gradient (4 ml of both 5% and 12%), followed by centrifugation at 80,000 g 
for 1h (SW41 Ti Rotor, Swinging Bucket, Beckman). A milky interface containing the 
synaptosomes was recovered from the layer between the 5% and 12% Ficoll layers; this was 
topped-up with sucrose buffer to 3 ml and centrifuged at 45,000 g for 25 min to pellet the 
synaptosomes (TLA-100 Rotor, Fixed Angle, Beckman). Purified synaptosomes were then 
sequentially extracted with buffers of increasing stringency: pH 6 (40 mM Tris-HCl, 2% Triton X-
100, 0.5 mM CaCl2), pH 8 (20 mM Tris-HCl, 1% Triton X-100), and SDS (5% SDS) as previously 
described [82]. The SDS buffer extract contains strongly PSD-associated proteins. All solutions 
contained protease inhibitors (Complete Protease Inhibitor Cocktail tablets, Roche) and phosphatase 
inhibitors (10mM NaF, 1mM Na3VO4 and 2mM Na4P2O7, all from Sigma). All centrifugations were 
carried out at 4 °C. For western blot analysis, the following primary antibodies were used: total Tau 
(Dako, polyclonal, 1:5,000), Fyn (BD Biosciences, 1:2,000), PSD95 (Millipore, 1:2,000), MAP2 
(Sigma, monoclonal, 1:1,000) and actin (monoclonal, Millipore, clone C4, 1:5,000). 
 
3.4.6 Image and data analysis 
 
Image analysis was carried out using Zen (Zeiss imaging) and Image-J (NIH imaging) software. For 
each group, in three independent experiments, at least 500 spines were analyzed from more than 20 
neurons. For the analysis, dendritic branches were selected from secondary dendrites. For each 
spine, a region of interest (ROI) in the spine head and one in the dendritic shaft were determined in 
the RFP channel, and also used for the Tau channel. Furthermore, for a subset of the samples we 
determined the mean intensity in the spine as a function of the mean intensity in the dendritic 
branch, followed by a Pearson correlation analysis. This single neuron analysis was done to rule out 
that spine localization of Tau is simply a reflection of higher expression levels. The average 
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intensity of Tau was measured in the ROI, subtracting the background of the image. Localization of 
the different tagged proteins to spines was determined by obtaining the ratio of the mean intensity in 
the spine to the mean intensity in the dendritic shaft for Tau, followed by normalization of the value 
obtained for RFP that distributes evenly throughout the dendrite and the spines. An unpaired t-test 
was used for statistical analysis.  
 
3.5 Results 
 
3.5.1 Endogenous Tau enters the dendritic spine, whereas MAP2 is confined to its neck 
 
Both Tau and MAP2 can be easily detected in primary neuronal cultures irrespective of their 
phosphorylation state. This differs from the immunohistochemical staining of wild-type mouse 
tissue, in which endogenous Tau, different from MAP2, is difficult to detect possibly because it is 
so tightly bound to microtubules that it cannot be labeled by Tau-specific antibodies [83]. As a 
primary hippocampal neuron differentiates, Tau and MAP2 begin to compartmentalize as shown for 
the processes and cell bodies with images taken from DIV1.5 (days in vitro 1.5) and DIV5 neurons, 
and Tau becomes enriched in axons whereas MAP2 becomes enriched in dendrites (Fig. 3.1 A-H). 
Given this distribution, it is not understood why the predominantly dendritic MAP2 cannot 
compensate for the absence of the primarily axonal Tau in TauKO mice, thereby targeting Fyn to 
dendritic spines, particularly because both MAP2 and Tau efficiently bind Fyn. By analyzing 
DIV20 wild-type hippocampal cultures and using actin staining via phalloidin to visualize the 
spines we found that both endogenous MAP2 and Tau are localized to dendrites; however, whereas 
Tau entered the spine head, MAP2 mostly remained localized in the dendritic shaft, entering the 
neck of only 6.5 % of spines (analysing 200 neurons) and never the spine head (Fig. 3.1 I-M). This 
might explain why MAP2 cannot compensate for Tau in localizing Fyn to the spine head.  
 
3.5.2 Over-expressed MAP2 is mainly excluded from spines, whereas P301L Tau is enriched  
 
We next aimed to determine whether over-expression of MAP2 would target it to the spine. We also 
investigated how spine localization of Tau is affected by the presence of the P301L mutation, by 
deleting functional domains of Tau, and by either introducing pseudophosphorylation sites or over-
expressing constructs in which critical phosphorylation residues had been mutated to alanine to 
abrogate phosphorylation (Fig. 3.2). All constructs were generated using the longest human Tau 
isoform, hTau40, as a template, and by adding a V5-tag at the carboxy-terminus (except for MAP2c 
and a-tubulin that were tagged with EGFP).  
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For all transfections, using triplicates, more than 500 spines were counted from at least 20 
secondary branches. We found that even full-length MAP2c, although targeted to the dendrite, was 
mainly excluded from spines, meaning that it was either not efficiently targeted to the spine head or 
not efficiently retained. This finding was obtained by comparing the distribution in the spine with 
that in the dendritic branch, using RFP that distributes throughout the entire cytoplasm and into the 
spines for normalization (Fig. 3.3 A, Fig. 3.6 A). As a control, we included EGFP-tagged a-tubulin 
(Fig. 3.3 B). When full-length Tau was over-expressed, it was targeted to dendritic spine heads at 
relatively low levels compared with RFP, whereas MAP2c showed no localization at all (Fig. 3.3 C, 
Fig. 6A). Confirming previous findings [17,64], P301L Tau was found to be targeted to the spine at 
a five-fold higher rate than non-mutated, wild-type Tau (P <0.001) (Fig. 3.3 D, Fig. 3.6 B). A 
Pearson correlation analysis revealed that the increased targeting of P301L Tau to spines is not 
because of an increased expression of P301L Tau compared with wild-type Tau (wild-type Tau: 
r=0.79, P=0.011; P301L Tau: r=0.72, P=0.015). 
 
To obtain a higher resolution of Tau localization, structured illumination microscopy (SIM) was 
used. This revealed that Tau in P301L Tau over-expressing neurons does not co-localize with 
PSD95 but may instead form a scaffold that supports the PSD (Fig. 3.3 E-G). 
 
3.5.3 Spine localization of mutants lacking PXXP motifs or the microtubule-binding domain  
 
We next compared the localization of different Tau truncation mutants to that of full-length Tau 
(Fig. 3.4 A): ∆Tau that comprises the projection domain and contains the first 255 amino acids of 
the Tau protein (based on the longest human Tau isoform) (Fig. 3.4 B), ∆MTB that lacks the MBRs 
but contains the projection domain as well as the carboxy-terminus of the protein (Fig. 3.4 C), and 
∆PXXP that lacks the seven PXXP binding motifs including those that interact with the SH3 
domain of Fyn (Fig. 3.4 D). By comparing the localization with that of full-length Tau, we observed 
a reduced localization of DTau to the dendrite, with a very low signal detectable beyond the 
primary dendrite (Fig. 3.4 B). This extends previous findings obtained in vivo [17]. ∆MTB was 
found to distribute as freely as RFP (P= n.s.), including into spines, suggesting that the binding of 
Tau to microtubules hinders its free distribution (Fig. 3.4 C, Fig. 3.6). The PXXP motifs of Tau are 
critical for the interaction of Fyn with Tau (Fig. 3.2). However, we found under conditions with 
physiological Fyn levels and activity that deletion of the PXXP motifs did not cause a difference in 
the targeting of Tau to the spine from that of the full-length construct (P= n.s.) (Fig. 3.4 D, Fig. 3.6).  
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Figure 3.3 
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Figure 3.3. Over-expressed MAP2 is mainly excluded from spines, whereas P301L Tau is 
enriched in spines. Wild-type neurons co-transfected with different V5-tagged expression 
constructs together with RFP to reveal dendrites and spines. (A) When full-length MAP2 tagged 
with EGFP is over-expressed, it is targeted to the dendrite but excluded from spines, which are 
visualized with RFP. (B) EGFP-tagged a-tubulin is included as control. (C) When full-length 
Tau is over-expressed, it is targeted to the dendrite but mostly excluded from spines. (D) In 
contrast, P301L Tau is targeted at high levels to the spine. (E-G) Structured illumination 
microscopy (SIM) was used to determine that when P301L Tau is over-expressed (E) it does not 
co-localize with PSD95 (F) in the spine (G, merge). A close-up is shown on the right for the area 
marked by a white box in G. Scale bar: 2 µm  
 
3.5.4 Pseudophosphorylation of distinct sites (AT180, 12E8, PHF1) alone is sufficient to target 
Tau to spines, different from the pseudophosphorylation of the late phospho-epitope S422 
  
Several of the 'classical' phosphorylation epitopes of Tau (e.g. AT180) are defined by two amino 
acid residues (T231/S235) and hence, for our study, both sites were mutated together. To assess the 
role of distinct phosphorylation sites in spine localization, we generated a series of constructs by 
changing serine, threonine and tyrosine residues either to alanine (A) to prevent phosphorylation, or 
to negatively charged glutamate residues (E) in order to mimic phosphorylation. We thus over-
expressed a series of Tau constructs that were tagged at the carboxy-terminus with a V5-tag (Fig. 
3.2): Y18A (mutating the tyrosine residue that is phosphorylated by Fyn) (Fig. 5A), AT180A (Fig. 
5B), AT180E (Fig. 3.5C), 12E8A (Fig. 3.5D), 12E8E (Fig. 3.5E), PHF1A (Fig. 3.5F), PHF1E (Fig. 
3.5G), S422A (Fig. 3.5H) and S422E (Fig. 3.5I). RFP was used to visualize the spines, with the 
relative quantification shown in Figure 3.6A. A Pearson correlation analysis revealed that, e.g., the 
increased targeting of AT180E Tau to spines is not because of an increased expression of this 
mutant compared with that of AT180A (AT180E Tau: r=0.81, P=0.008; AT180A Tau: r=0.84, 
P=0.004) (Fig. 3.6C). The analysis revealed that all A mutants were precluded from entering the 
spines beyond the levels found for non-mutant, full-length Tau. Of the E mutants, all but the S422E 
mutant showed an increase in spine localization that was in the order of 4-5.5-fold. Together these 
findings indicate that (i) phosphorylation levels are low under normal conditions, (ii) introducing a 
pseudophosphorylation at one site is sufficient to target Tau to the spine, and (iii) S422 behaves 
differently from the other investigated phospho-epitopes, possibly reflecting the fact, as shown in 
animal studies, that this is an epitope that is phosphorylated relatively late in disease (i.e., when Tau 
filaments have already formed) [84]. The S422 site may thus have no role in regulating the 
subcellular distribution of Tau, different from Y18, T231/S235 (AT180), S262/S356  
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Figure 3.4 
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Figure 3.4. Spine localization is facilitated by the deletion of the microtubule-binding 
domain. (A) When wild-type Tau is over-expressed it distributes throughout the neuron but is 
mostly excluded from the spines (see close-up, and RFP localization that was used as a positive 
control for spine localization. The RFP signal in zoom view was enhanced to better visualize the 
structure of the dendrite and spine). (B) ∆Tau displays reduced localization to the dendrite, with 
a very low signal detectable beyond the primary dendrite. (C) ∆MTB lacks the region containing 
the MBRs and distributes freely, including into spines. (D) Deletion of the PXXP binding sites 
that interact with the SH3 domain of Fyn does not result in spine localization that is different 
from that of wild-type Tau. Scale bar: 20 µm  
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Figure 3.5. Pseudophosphorylation of distinct sites (AT180, 12E8, PHF1) alone is sufficient 
to target Tau to spines, different from the pseudophosphorylation of the late phospho-
epitope S422. Tau was over-expressed in primary neuronal cultures, with spine targeting 
determined for different V5-tagged Tau constructs: Y18A (A), AT180A (B), AT180E (C), 
12E8E (D), PHF1E (E), AT180E (F), AT180A (G), S422A (H) and S422E (I). RFP was used to 
visualize the spines. Merged images are shown for Tau (in green) and RFP (in red). Scale bar: 4 
µm 
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Figure 3.6 
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Figure 3.6. Quantification of the spine targeting ratio of MAP2, wild-type Tau and Tau 
mutants. (A) Quantification of relative spine levels by determining the ratio of the mean 
intensity in the spine compared to the dendrite for each transfectant, followed by normalization 
of the value obtained for RFP, which distributes evenly throughout the dendrite and the spines. 
For each experimental group, in three independent experiments, at least 500 spines were 
analyzed from more than 20 neurons each (***P <0.001). (B, C) Pearson correlation coefficient 
analysis of two representative pairs of transfected neurons, with the imaging done at the single 
neuron level (wild-type Tau: r=0.79, P=0.011; P301L Tau: r=0.72, P=0.015; AT180E Tau: 
r=0.81, P=0.008; AT180A Tau: r=0.84, P=0.004). 
 
 
 (12E8) and S396/S404 (PHF1). The strongest localization effect (when considering the A/E ratio) 
was seen for the AT180 epitope, which was therefore analyzed further. 
 
3.5.5 AT180E Tau is targeted to the spine whereas AT180A is excluded from it 
 
Interestingly, the AT180 epitope (a site that is hyperphosphorylated in AD) overlaps with the 
seventh PXXP motif (pT231PPKS235P) that has a role in the interaction of Tau with both Fyn and the 
protein phosphatase PP2A [27]. We co-transfected wild-type neurons with a V5-tagged AT180E 
construct and a myc-tagged AT180A construct and performed immunocytochemistry and confocal 
microscopy. The A and E channels were exposed to the laser power so as to obtain an unsaturated 
and comparable signal intensity in the branch, allowing for a comparison of the signal intensity in 
the spine (Fig. 3.7). Using RFP as a marker, we confirmed that even under co-expression 
conditions, AT180A is mainly excluded from spines, whereas a significant proportion of AT180E 
in the same neurons is localized to the spines.  
 
3.5.6 Absence of Fyn does not abolish Tau targeting to spine 
 
Tau has previously been shown to be required for the targeting of Fyn to the dendritic compartment 
and, more specifically, the spine [17]. To determine whether the opposite relationship also exists, 
namely that Tau localization to spines is Fyn-dependent, we determined for a series of mutants with 
prevalent spine localization (P301L, AT180E, 12E8E and PHF1E) whether this localization was 
altered compared to wild-type neurons, when the Tau mutants were over-expressed in FynKO 
primary neuronal cultures (Fig. 3.8A). We also included the AT180A mutant that in wild-type 
neurons is mainly excluded from the spine (Fig. 3.5, 3.7). We found that spine localization was  
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Figure 3.7. AT180E Tau is targeted to spine whereas AT180A is excluded from it. Wild-type 
neurons were co-transfected with AT180E-V5 and AT180A-myc followed by 
immunocytochemistry and confocal microscopy. The A and E channels were exposed to the 
laser power so as to obtain a comparable signal intensity in the branch, thereby allowing for a 
comparison of the signal intensity in the spine. (A) AT180E-V5, (B) AT180A-myc, (C) RFP, 
and (D) merge. A close-up is shown in the second row of images for the area marked by a box in 
D, with arrows pointing at spines. (E) Line profile of a selected spine (see section in close-up 
below D) revealing that AT180A is mainly excluded from the spine whereas a significant 
fraction of AT180E is localized to the spine (indicated by arrows). Scale bar: 10 µm (A-D) 
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Figure 3.8. Absence of Fyn does not abolish Tau targeting to spine. (A) When Tau is over-
expressed in FynKO primary neuronal cultures, the localization of phospho-Tau mutants does not 
differ from that in wild-type neurons. (B) For each experimental group, in three independent 
experiments, at least 500 spines were analyzed from more than 20 neurons each. A slight 
reduction in spine localization is seen for P301L Tau when Fyn is absent (*P<0.05). 
 
not affected by deletion of Fyn. In the case of the P301L Tau mutant, there was a slight reduction in 
spine localization when Fyn was absent, although the biological significance of this finding remains 
to be determined (Fig. 3.8B).  
 
Using biochemical methods, we have previously reported that levels of synaptic Fyn are reduced by 
73% and 62% in synaptosomal PSD95 fractions obtained from pooled hippocampi of ∆Tau 
transgenic and TauKO mice, respectively, compared to wild-type controls [17,35]. We thus obtained 
brain extracts and synaptosomal PSD fractions by sucrose fractionation from total forebrains of 
wild-type, FynKO and P301L mutant Tau transgenic pR5 mice and analyzed these for levels of Fyn, 
Tau, MAP2, actin and PSD95 (Fig. 3.9). Loading equal amounts of protein (10 µg), the analysis 
revealed that neither total (normalized for actin, P= 0.75) nor synaptosomal levels (normalized for 
PSD95, P= 0.12) of Tau differed when FynKO was compared with wild-type (Fig. 3.9). While this 
analysis demonstrates that the absence of Fyn does not abolish the targeting of Tau to the spines, it 
does not rule out that Fyn has a role when this kinase is over-activated as is the case in AD. We also 
found, confirming the above spine localization analyses, that whereas MAP2 was present in total 
extracts, it was absent from the synaptosomal preparation. 
 
3.6 Discussion 
 
In the present study, we expressed different truncated, pseudophosphorylated and alanine-mutated 
forms of the microtubule-associated protein Tau in primary hippocampal neurons, to determine 
what factors dictate the localization of Tau to dendritic spines, as well as the role of Fyn in this 
process. We also compared the spine localization of both endogenous and over-expressed Tau with 
that of MAP2, a microtubule-binding protein that is mainly localized to the dendritic compartment 
of mature neurons. 
 
We firstly found in mature primary hippocampal cultures obtained from wild-type mice that 
endogenous Tau is targeted to the spine, albeit at low levels. This extends our previous findings,  
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Figure 3.9 
 
 77 
Figure 3.9. Absence of Fyn does not affect levels of Tau is synaptosomal fraction. (A) Total 
brain extracts and synaptosomal PSD95 fractions obtained by sucrose fractionation from wild-
type (WT), Fyn knock-out (FynKO) and P301L mutant Tau transgenic pR5 mice (Tautg) analyzed 
for the presence of Tau, MAP2, Fyn, PSD95 and actin. Human (hu) and endogenous mouse (mo) 
Tau are indicated by arrows. Neither total (normalized for actin, P= 0.75) nor synaptosomal Tau 
levels (normalized for PSD95, P= 0.12) are reduced in wild-type compared to FynKO extracts. 
 
 
obtained in brain sections and by fractionation, that a small proportion of Tau is localized to the 
dendritic compartment under physiological conditions [17]. Interestingly, there is evidence for brain 
region-specific differences in this localization, with Hoffmann and colleagues reporting the 
presence of hyperphosphorylated Tau in dendritic spiny protrusions of CA3 hippocampal neurons, 
but not in the dendritic spines of pyramidal neurons of cortical layer V [85]. The same study also 
demonstrated the absence of Tau from the spines of neurons in which the somatodendritic 
compartment was almost completely filled with filamentous hyperphosphorylated Tau. Although 
the reason for this brain region specificity is not understood, differences in the principal cytoskeletal 
elements in hippocampal versus cortical spines may have a role. Unlike dendritic spines of cortical 
pyramidal neurons, which have an actin-based cytoskeleton, the CA3 thorny excrescences 
occasionally contain microtubules [86,87]. Indeed, in our confocal analysis of hippocampal 
cultures, we found low levels of tubulin staining in the dendritic spines (data not shown).  
 
We next analyzed MAP2 as the 'typical' dendritic representative of the MAP family. Interestingly, 
MAP2 was mostly restricted to the dendritic shaft and only occasionally entered the neck of the 
spine, whereas Tau entered the spine head. This finding is supported by the western blot analysis, 
which revealed an absence of MAP2 in the synaptosomal fraction. Together this would explain why 
MAP2 cannot compensate for the absence of Tau in TauKO mice in targeting the tyrosine kinase Fyn 
to dendritic spines, despite the fact that both Tau and MAP2 share crucial binding sites for Fyn and 
the serine/threonine-directed phosphatase PP2A, which both directly and indirectly regulates Tau 
phosphorylation [27,50,51,88]. What remains unexplained is why MAP2 does not enter the spine 
head. Even by increasing the expression levels by over-expressing MAP2, no strong staining 
intensity was revealed in the spine head, which indicates that MAP2 is either not efficiently targeted 
or not efficiently retained.  Because MAP2 is a relatively large scaffolding protein, it might be 
bound to the microtubules in the dendritic branches more tightly than Tau, such that it that it is less 
dynamic and cannot be released efficiently into the spine. 
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We also found that, unlike over-expressed wild-type human Tau, FTD-linked mutant P301L Tau is 
efficiently targeted to the spine head. This might explain why expression of this P301L mutant form 
of Tau in transgenic mice, combined with Ab, causes a particularly strong pathology and early 
lethality[35]. Strong effects of mutant Tau on spines have been demonstrated in several studies. For 
example, expression of mutant Tau in vivo has been shown to affect spine morphology and 
eventually cause spine loss [89], a phenotype that is augmented by Aβ [90,91]. In P301S Tau mice, 
the fraction of thin spines was found to be strongly reduced, whereas that of mushroom spines was 
found to be increased compared to controls [85]. Another study reported that, even at an early age, 
P301S Tau transgenic mice are characterized by a lower average spine density, length, area and 
volume compared with wild-type mice, concomitant with an impaired learning at this age in the 
Morris water maze [92]. Together with our findings this reveals that FTD mutant forms of Tau 
accumulate in the spine, which results in morphological changes and, subsequently, spine loss. 
 
Our hippocampal primary culture study also revealed that a mutant form of Tau that only comprises 
the projection domain (∆Tau) does not travel efficiently beyond the primary dendrite, supporting 
previous findings of dendritic exclusion of ∆Tau [17,93]. A second deletion construct, ∆MTB, 
lacked the MBRs but contained the projection domain as well as the carboxy-terminus. This form of 
Tau was found to distribute freely, including into the spines, suggesting that trapping of Tau by 
binding to microtubules, the major interaction partner of Tau [94], hinders its free distribution 
throughout the neuron. When we deleted the PXXP motifs of Tau (a domain retained in the DTau 
mutant and required for interaction with the SH3 domain of Fyn), the localization of this construct 
to spines did not differ from that of wild-type Tau. We had expected that the spine targeting ratio 
would be further reduced but because this ratio is already low for wild-type Tau our method may 
not have been sensitive enough to reveal a difference.  
 
Although truncation of Tau is increasingly being shown to have a role in pathogenesis[95], 
phosphorylation remains an important post-translational modification of Tau, and 
hyperphosphorylated Tau has a critical role in AD pathogenesis. In our mutagenesis study, we 
showed that Tau is massively targeted to the spine when the AT180, 12E8 and PHF1 phospho-
epitopes are pseudophosphorylated, using alanine mutant forms as a control. Targeting occurred to 
a similar degree as for the P301L mutant. Interestingly, the S422 epitope behaved differently, as 
both the A and the E mutants revealed the same weak localization to spines. We deliberately did not 
use GFP-tagged versions of Tau, as we have found that tagging Tau with GFP instead of V5 
abrogates the exclusion of spine localization seen for V5-tagged wild-type Tau (data not shown). 
Hoover and colleagues, in contrast, used GFP-tagged Tau for expression and in addition expressed 
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the shorter human 0N4R isoform of Tau [64], whereas we expressed the longest isoform, 2N4R, 
tagged with V5. In the former study, 14 serine and threonine residues were simultaneously changed 
to either alanine (termed AP), or glutamate (termed E14), resulting in an approximately four-fold 
increase in the spine localization of E14 Tau and a four-fold decrease in the localization of AP 
compared to wild-type Tau. In our study we refrained from mutating 14 sites simultaneously and 
rather mutated individual sites, although we had previously generated transgenic mice expressing 
E10-mutated Tau [96]. Our approach of mutating single phospho-epitopes allowed us to 
demonstrate that not all sites mediate spine localization equally (AT180, 12E8 and PHF1 do, 
whereas S422 does not), and to show that introducing a single pseudophosphorylation epitope is 
sufficient to target Tau efficiently to the spine. One would conclude that in primary hippocampal 
neurons Tau is normally not highly phosphorylated because, if it were, phosphorylation at any 
epitope that had not been mutated to alanine should overcome the exclusion conferred to these 
mutant forms as far as spine localization is concerned. Interestingly, the S422E mutant is not 
efficiently targeted to the spine nor does its localization differ from that of the A mutant, suggesting 
that phosphorylation of this epitope has no role in subcellular Tau targeting. This is supported by 
the notion that this epitope is only phosphorylated under pathological conditions, with evidence 
from animal studies suggesting that this site is phosphorylated only when Tau filaments have 
formed, i.e. relatively late in the AD disease process [84]. 
 
We have previously shown that Tau is critically required to target Fyn to dendritic spines where this 
kinase phosphorylates the NMDA receptor, a prerequisite for recruiting PSD95 into a protein 
complex that then mediates the excitotoxic signaling triggered by Aβ [17]. In our study we 
therefore aimed to determine whether Fyn has a role in targeting endogenous Tau to the 
synaptosomal compartment. We found that the absence of Fyn did not abolish spine targeting of 
Tau. With Fyn activation having a prominent role in AD [34], our study does, however, not imply 
that Fyn has no role in phosphorylating and targeting of Tau in a pathological context. How Tau is 
localized in the presence of over-activated Fyn has not been addressed in our study. Also, as far as 
the interaction between Fyn and Tau are concerned, it remains to be determined whether Tau and 
Fyn form a complex when traveling into the spine or whether their effect is mediated independent 
of a direct interaction. Possible scenarios as to how these two molecules might interact have been 
discussed previously [61].  
 
3.7 Conclusion 
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In conclusion, we have shown that endogenous Tau and MAP2 display differences in spine 
localization, with Tau entering the spine head, whereas MAP2 only enters the neck and does so 
infrequently. We have also revealed a crucial role for the MBR domain in the targeting of Tau to 
the spine, and have further demonstrated that spine targeting depends on distinct phosphorylation 
sites, and can occur independent of Fyn. This does not rule out, that in the presence of activated 
Fyn, Tau's targeting to the dendritic spine is modulated. 
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Chapter 4. Trafficking of endogenous Tau using               
genome-edited Tau-mEOS2 mice 
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4.1 Preface 
 
The MAPT locus encoding Tau is huge, having in humans a size of 134 kb 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=MAPT). This locus contains various control 
elements that dictate not only alternative splicing, but also subcellular targeting of the mRNA and 
expression levels, and capturing this complexity by expressing Tau-encoding cDNAs is impossible. 
In neurons, Tau mainly targets to the axons, with only weak expression in dendrites. Most in vitro 
and in vivo models investigating Tau use overexpression approaches that have shown non-specific 
expression of Tau in all cellular compartments, indicating that over-expression may compromise 
Tau trafficking and cause artifacts. To overcome this drawback, new approaches are needed. We 
therefore decided to directly visualize endogenous Tau proteins by introducing a fluorescence tag 
such as the photo-convertible mEOS2 or EGFP cassette into the MAPT locus to tag endogenous Tau.  
 
The literature at the time suggested three principal approaches. The first one is called 'gene trap 
strategy' using mouse embryonic stem (ES) cells, which is a well-established method but is also 
quite time consuming, realistically requiring in the order of two years to generate knock-in mice. 
The second approach uses a genome editing tool called Zinc finger nucleases (ZFN). However, this 
method is very expensive and only available through a commercial source (Sigma) which may 
potentially cause IP issues. Then, we noticed that a new alternative genome editing strategy called 
TALEN had emerged. TALEN is a highly modulated system that allows a laboratory using a PCR 
library and online bioinformatics tools to design, clone TALENs and target any genomic locus 
using traditional mouse zygote microinjection. This method usually costs less and it takes less than 
a year to generate a knock-in animal. Although we were not familiar with genome editing 
techniques, we were quite keen to take the risk and start this project.  
 
Using TALEN, we successfully established a Tau-mEOS2 knock-in mouse line with a mEOS2 gene 
tagged in frame to the carboxy-terminus of the MAPT locus. We determined the subcellular 
localization and dynamics of Tau-mEOS2 using live cell imaging, photo-conversion and FRAP 
assays. Our results clearly show that at early developmental stages Tau-mEOS2 followed a 
proximo-distal gradient in axons that was similar to that of endogenous Tau in neurons obtained 
from wild-type mice. We have also confirmed the existence of Tau expression in the somato-
dendritic compartment.  Using the FRAP assay, we further revealed that the mobility of Tau in 
dendrites and axons of Tau-mEOS2 neurons was reduced compared with that of overexpressed Tau. 
Importantly, our most recent experiment has proved that Tau-mEOS2 can be photo-converted 
making the transgenic line suitable for single particle tracking experiments (using sptPALM, data 
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not shown). This will allow us to study Tau dynamics at the endogenous level in order to address 
some of the most important questions in the field, such as how Tau accumulates in the 
somatodendritic compartment and in spines.  
 
This part of work has been published by Scientific Reports.  
 
Xia, D., Gutmann, J. M., & Götz, J. (2016). Mobility and subcellular localization of 
endogenous, gene-edited Tau differs from that of over-expressed human wild-type and 
P301L mutant Tau. Scientific Reports, 6, 29074.  
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4.2 Abstract  
 
Alzheimer's disease (AD) and a subset of frontotemporal dementia termed FTLD-Tau are 
characterized by a massive, yet incompletely characterized and understood redistribution of Tau. To 
establish a framework for understanding this pathology, we used the genome-editing tool TALEN 
and generated Tau-mEOS2 knock-in mice. We determined the mobility and subcellular localization 
of endogenous Tau in hippocampal cultures,  at three stages of maturation using live-cell imaging, 
photo-conversion and FRAP assays. Tau-mEOS2 cultures were compared with those over-
expressing EGFP-tagged forms of human wild-type (hWT-Tau) and P301L mutant Tau (hP301L-
Tau), modelling Tau accumulation in AD and FTLD-Tau, respectively. In developing neurons, Tau-
mEOS2 followed a proximo-distal gradient in axons and a subcellular distribution similar to that of 
endogenous Tau in neurons obtained from wild-type mice, which were abolished when either hWT-
Tau or hP301L-Tau was over-expressed. For the three conditions, FRAP analysis revealed a similar 
mobility in dendrites compared with axons in either Tau-mEOS2 or Tau overexpressed neurons; 
however, Tau-mEOS2 was less mobile than hWT-Tau and hP301L-Tau and the mobile fraction was 
smaller, possibly reflecting less efficient microtubule binding of Tau when over-expressed. 
Together, our study presents Tau-mEOS2 mice as a novel tool for the study of Tau in a 
physiological and a pathological context.  
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4.3 Introduction  
 
Tau is a microtubule-associated protein that is enriched in neurons, where it is expressed as multiple 
isoforms. In the human central nervous system, there are six low molecular-weight isoforms that are 
generated by alternative splicing [97-99]. This results in isoforms that have either 0, 1 or 2 N-
terminal inserts (0N, 1N and 2N) and either three (3R) or four (4R) microtubule binding domains 
[100]. Tau is developmentally regulated in humans, with the foetal isoform corresponding to the 
shortest of the six adult isoforms [101,102]. Mice, in contrast, express only 4R isoforms in 
adulthood whereas in the foetal brain the major isoform is 3R0N [103,104]. 
 
A major interest in Tau stems from the fact that this protein forms insoluble aggregates known as 
neurofibrillary tangles (NFTs) in many neurodegenerative disorders that are collectively termed 
tauopathies. These disorders include Alzheimer's disease (AD), which is also histopathologically 
characterized by plaques that are composed of aggregated, fibrillar forms of the peptide amyloid-β 
(Aβ) [105]. Tau pathology in the absence of an overt Aβ pathology is characteristic of a subset of 
frontotemporal dementias (FTD; also termed frontotemporal lobar degeneration, FTLD-Tau [106]). 
Not surprisingly, many studies of Tau function use over-expression systems, both in cell culture and 
in animal models, in order to better understand how Tau (with or without FTLD mutations) causes 
neurodegeneration and ultimately dementia. One of the more prevalent FTLD mutations is P301L 
that was one of the earliest pathogenic mutations to be identified in FTLD [19,107,108]. 
Mechanistically it has been shown that the mutations reduce microtubule binding and facilitate Tau 
polymerization [109,110]; other mutations have been shown to affect the association of Tau with 
the plasma membrane [10]. Many wild-type (WT) and FTLD mutant forms of Tau have been 
expressed in mice, with transgenic expression of human P301L Tau facilitating NFT formation at 
an early age, different from human WT Tau-expressing mice where NFT formation is delayed [3]. 
These animal studies have been complemented by other investigations in cell lines which have 
shown, for example, that transient expression of WT or disease-linked mutations 
of Tau (R406W, P301L, ΔN296) had a dramatic effect on the microtubule cytoskeleton as observed 
by immunofluorescence microscopy [111]. Additional insight has been gained in the roundworm C. 
elegans where the Tau homologue Ptl-1 has been shown to regulate structural neuronal integrity 
[112,113]. 
 
In vivo, Tau has been reported to be an axonal protein under physiological conditions, although a 
role has also been demonstrated in the dendritic compartment where levels are considerably lower 
[17,36]. In neuronal cultures, Tau has been shown to be ubiquitously expressed, with an enrichment 
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being reported in the axonal compartment [114]. In tauopathies, Tau accumulates in the 
somatodendritic domain. Synaptic activation has been demonstrated to cause the accumulation of 
Tau in spines by a process that is impaired by Aβ [76]. On the other hand, P301L Tau has been 
shown to accumulate in an Aβ-dependent manner in spines in vivo [17]. Similarly, over-expression 
of P301L Tau was also found to cause increased spine localization [115]. Together, these findings 
demonstrate that Tau localization to spines is tightly regulated. 
 
In order to determine how Tau accumulation impairs neuronal function, it is important to 
understand how the protein is distributed in neurons, how it is localized, and the nature of its 
mobility characteristics. A few studies have assessed the transport of Tau under both physiological 
and pathological conditions, leading to the claim that, at least in axons, Tau is transported 
anterogradely through a combination of free diffusion and transient association with microtubules, 
hopping from microtubule to microtubule ('kiss and hop'), with a reported 40 ms dwell time [116], 
and diffusing along the microtubule lattice [117]. Some studies assessing Tau transport have also 
applied newer microscopy methods such as FRAP (Fluorescence Recovery After Photobleaching) 
or sptPALM (single particle tracking Photo-Activated Localization Microscopy) [118] to over-
expression systems [119]. Here, we generated a novel mouse strain using the genome editing tool 
TALEN to equip endogenous Tau (with its multiple isoforms) with an EOS tag that could be used 
to track Tau and conduct photo-conversion. We then assessed the behaviour of the tagged Tau and 
compared it to that of over-expressed human WT (hWT-Tau) and P301L mutant Tau (hP301L-Tau). 
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4.4 Materials and Methods  
4.4.1 Ethics statement 
 
All experimental procedures in this study were conducted under the guidelines of the Australian 
Code of Practice for the Care and Use of Animals for Experimental Purposes and were approved by 
the University of Queensland Animal Ethics Committee (QBI/412/14/NHMRC; 
QBI/027/12/NHMRC). Mice were maintained on a 12-hour light/dark cycle and housed in a PC2 
facility with ad libitum access to food and water. 
 
4.4.2 Generation of Tau-mEOS2 mice using TALEN gene editing  
 
Mice with an EOS cassette inserted into the carboxy-terminus of the open reading frame of the tau-
encoding MAPT gene (Tau-mEOS2 mice) were generated using the TALEN gene editing tool. 
Three TALEN pairs that target a sequence near the stop codon of exon 12 of MAPT were designed 
using the online tool “TAL Effector Nucleotide Targeter 2.0” (https://tale-nt.cac.cornell.edu/node 
/add/talen). Three TALEN pairs that were predicted to yield a high targeting efficiency and low off-
target effects were selected and assembled using the TALEN toolkit (Addgene Kit # 1000000019) 
and the PCR-golden gate ligation method [120]. A donor construct comprising the mEOS2 cassette 
flanked by 500 bp long arms both upstream and downstream of the genomic sequence containing 
the MAPT stop codon was PCR-amplified and subcloned into the pGEM-T easy vector (Promega) 
using the NEB Gibson assembly kit. TALEN activity was evaluated in N2A cells using the T7E1 
assay. The pair that gave the highest activity was then used for in vitro transcription, using the 
Ambion megascript T7 kit. TALEN mRNAs (10 ng/µl each) were combined with the donor 
construct (15ng/µl) and injected into pronuclei of C57BL/6 single cell mouse embryos followed by 
transfer into pseudo-pregnant foster mice.  
The following primer pairs were used to identify offspring (F0) animals with a correct in-frame 
mEOS2 targeting event.  
Primer P1 (forward): 5'-CTATCTCTGACTCATTCTGTCAAATCTT-3',  
Primer P2 (reverse): 5'-GAAACGACTGCTTAAAATAGTCTTGTAT-3', 
Primer P3 (forward): 5'-CGTAAACGGGCACCACTTTGTGATCGACGG-3', and 
Primer P4 (reverse): 5'-GATACAGTGGCTGTGTGAGGGATGGGAGGC-3'. 
The PCR products obtained with primers pairs A/A' and B/B' were gel-purified and subcloned into 
the pGEM-T easy vector for sequence verification using the following primers: 
T7 : 5'-TAATACGACTCACTATAGGG-3', and  
SP6: 5'-ATTTAGGTGACACTATAG-3'. 
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4.4.3 Real-time quantitative PCR analysis 
 
For real-time quantitative PCR (RT-qPCR), left brain hemispheres were dissected and homogenized 
in TRIzol buffer (Thermo Fisher Ambion) for mRNA extraction. A reverse transcription kit 
(Thermo Fisher Invitrogen) was used to synthesize cDNA, followed by incubating the cDNA with a 
SYBR Green master mix (Bio-Rad) to perform an RT-qPCR reaction (C1000 Touch Thermo Cycler 
operating with the CFX384 Optical Reaction Module).  
The following primers used were: 
Mouse Mapt forward, 5’-GACCTAAAGAATGTCAGGTCG-3’; 
Mouse Mapt backward, 5’-GACGTGTTTGATATTATCCTT-3’; 
Mouse Gapdh forward, 5’-AACTTTGGCATTGTGGAAGG-3’ 
Mouse Gapdh backward, 5’-GGATGCAGGGATGATGTTCT-3’ 
 
4.4.4 Primary hippocampal cultures 
 
Embryonic day (E)17 or E18 hippocampal neurons were obtained from WT, Tau knock-out (KO) 
[121], and Tau-mEOS2 mice and plated onto poly-L-lysine coated coverslips in a 12-well plate at a 
density of 80,000 cells/well [80]. For their culture, Neurobasal medium (Gibco) was supplemented 
with 5% foetal bovine serum (Hyclone), 2% B27, 2 mM Glutamax (Gibco) and 50 U/ml penicillin/ 
streptomycin (Invitrogen). The medium was changed to serum-free Neurobasal medium 24 h post-
seeding and half the medium was changed twice a week. For live-cell confocal imaging, 200,000 
cells were plated into 35 mm glass-bottom dishes (In Vitro Scientific) using the above medium, 
which was replaced by phenol red-free Neurobasal medium 24 h later.  
 
4.4.5 Western blot analysis and immunocytochemistry 
 
For western blot analysis and immunocytochemistry, two Tau-specific antibodies were used: total 
Tau (Dako, polyclonal, 1:5,000), and Tau5 (Thermo Fisher, monoclonal, 1:5,000). Both IRDye 
800CW goat anti-rabbit IgG and IRDye 680RD goat anti-mouse IgG (Licor) were used as 
secondary antibodies for western blot analysis. For immunocytochemistry in combination with 
Tau5, Alexa Fluor 555-labelled goat-anti-mouse antibody (LifeTechnologies, Thermo Fisher, 1:500) 
was used for detection. To detect actin, phalloidin-Alexa Fluor 647 (New England Biolabs, 1:100) 
was used.  
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4.4.6 Live cell imaging, FRAP assay and photo-conversion 
 
Primary neurons were transfected using Lipofectamine 2000 and used for live-cell imaging 24 to 48 
h post-transfection. The following constructs were used for transfection: hTau-EGFP (human full-
length 2N4R Tau with carboxy-terminally tagged EGFP), hP301L-EGFP (FTD P301L mutant 
2N4R Tau with carboxy-terminally tagged EGFP), Lifeact-RFP (pmTagRFP-T-Lifeact-7, Addgene 
Plasmid #54586), and Lifeact-EGFP (kindly provided by Dr. Fred Meunier). Photo-conversion was 
achieved using the 405 nm UV laser on the LSM710 confocal microscope (Zeiss). For the FRAP  
assay, DIV 18-21-transfected neurons were analysed using a Zeiss LSM 710 confocal microscope 
equipped with a 5% CO2, 37 °C humidified cage. Time-lapse images of the GFP and RFP channels 
were captured with a Zeiss Plan-Apochromat 63x Oil DIC (N.A. = 1.4) objective at 2 s intervals 
using a 4× optical zoom. Regions of interest (ROIs) of the same size or length in the spine, axon or 
dendrite were photo-bleached by scanning with a 405 nm and 488 nm laser, respectively, combined 
at the maximum power, at a scanning speed of 3.5 µs/pixel which was repeated five times. Images 
were analysed using Image J and Prism 6. For each ROI, the total intensity was measured and 
background intensities were subtracted. A dendritic or axonal region away from the FRAP ROIs 
was used to compensate for the fluorescence loss during image acquisition. Data from different 
cells were normalized  to pre-bleaching as 100% and immediately post-bleaching as 0%. The 
following formula was used for the fitting of FRAP curves:  % Recovery = (1 – e-Kt) · 100%, with 
K being the recovery rate constant, and (t1/2) the half-time = ln(2)/k (half-time being the time 
required for fluorescence to reach 50% recovery).  Data are presented throughout as mean ± SEM. 
 
4.5 Results 
 
4.5.1 Tau-mEOS2 knock-in mice generated with the genome-editing tool TALEN express all 
three major central nervous system Tau isoforms  
 
The protein Tau is encoded by the MAPT gene, and alternative splicing generates multiple isoforms. 
To visualize all forms of endogenous Tau in vivo, we established a novel transgenic mouse line by 
introducing a photo-convertible mEOS2 tag in-frame into the carboxy-terminus of the MAPT gene, 
using the genome-editing tool TALEN [119] (Fig. 4.1a). Three TALEN pairs predicted to yield a 
high targeting efficiency and to have low off-target effects were designed and assembled using the 
TALEN toolkit provided by the Zhang Laboratory (Addgene Kit # 1000000019). A donor construct 
comprising the mEOS2 cassette flanked by 500 bp long arms both upstream and downstream of the 
genomic sequence containing the MAPT stop codon was designed (Fig. 4.1b). The TALEN reaction 
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was established in N2A cells by evaluating three TALEN pairs for genome-editing activity using 
the T7 endonuclease I assay (data not shown). The pair with the highest activity was used for in 
vitro transcription, and the thereby generated TALEN mRNAs were combined with the donor 
construct and injected into pronuclei of C57Bl/6 single cell mouse embryos by classical 
transgenesis [52], followed by transfer into pseudo-pregnant foster mice. To identify animals among 
the offspring (F0) that had undergone an mEOS2 targeting event, flanking PCR genotyping was 
performed, using two primer pairs (P1/P2 and P3/P4), with one primer binding to the mEOS2 
sequence (P3, P4), and the other flanking primer binding to regions outside the donor construct 
sequence, one upstream of the left arm (P1) and the other downstream of the right arm (P4) (Fig. 
4.1c). Of a total of 120 offspring, two mice (#90 and #120) were identified as positive. To ensure 
that the recombination had not induced INDEL (insertion or deletion) mutations, we PCR-amplified 
the top 5 predicted off-target sites (using the above software) and conducted Sanger sequencing; 
this confirmed the absence of mutations (data not shown).  
 
We next established two homozygous Tau-mEOS2 mouse lines (TauEOS90 and TauEOS120) 
employing a sequential breeding procedure. We performed an initial analysis that included western 
blotting and the establishment of primary neuronal cultures with both strains, and found no overt 
differences between them. Since they are genetically the same, we only used the TauEOS90 strain, 
which is referred to as Tau-mEOS2 from here on (Western blot analysis using a pan-Tau antibody 
(DAKO Tau) and including WT and Tau knock-out samples [121] as controls confirmed that the 
size of the Tau-mEOS2 was about 75 kDa. As predicted, this is approximately 25 kDa larger than 
endogenous Tau, indicating correct targeting of the mEOS2 cassette (Fig. 4.1d). Tau is an unusual 
protein in that its longest human brain isoform contains 80 serine and threonine residues and 5 
tyrosine residues, many of which are phosphorylated under physiological conditions. Owing to its 
basic amino acid content, its heterogeneous phosphorylation and the existence of multiple isoforms, 
the protein runs like a smear, and the individual isoforms can only be resolved by treating the 
extract with protein phosphatase [99,122]. By incubation with lambda phosphatase, the three 
murine central nervous system isoforms were revealed with a 0N:1N:2N ratio similar to that in WT 
mice, indicating that alternative splicing is maintained in the Tau-mEOS2 mice; the ratio in WT 
mice was 81:8.5:10.5, and the ratio in the Tau-mEOS2 mice was 70.5:8:21.5 (Fig. 4.1e). By 
titrating Tau-mEOS2 against WT extracts, we also found that the level of Tau expression was 
approximately fifteen-fold less than that of WT (Fig. 4.1d). To determine whether this was a 
reflection of reduced transcript levels, we used qRT-PCR and found an almost three-fold reduction 
in the levels of Tau-mEOS2 compared to WT Tau, suggesting that the tag interferes with either the 
transcription or turnover of Tau-mEOS2 mRNA (Fig. 4.1f). The Tau-mEOS2 mice, upon gross 
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analysis, did not display any impairments. Together, these findings demonstrate that the Tau-
mEOS2 strain is overtly normal, despite significantly reduced Tau levels, presenting it as a tool for 
the analysis of Tau mobility and subcellular localization in response to both internal and external 
stimuli. 
4.5.2 Over-expression of WT and P301L mutant Tau reverses the axo-dendritic gradient and 
abolishes the proximo-distal gradient in the axons of Tau-mEOS2 hippocampal cultures  
 
Tau is conventionally treated as an axonal protein; however, we and others have previously 
demonstrated that, even under physiological conditions, Tau is also present in the dendrites and in 
spines, albeit at lower levels [17].Tau has been further localized to neuronal nuclei; it has also been 
found in nuclear fractions, in isolated intact nuclei and as speckles in the nuclei of SH-SY5Y but 
not N2a neuroblastoma cells [123]. These analyses used Tau-specific antibodies and, as far as 
conventional immunohistochemistry is concerned, required antigen retrieval methods, unless Tau 
was over-expressed as is the case for Tau transgenic mice that model the Tau pathology in AD and 
FTD [83]. What these data illustrate is the complexity in revealing the distribution of Tau, some of 
which may reflect nonspecific binding of the different anti-Tau antibodies that have been employed.  
 
To clarify whether Tau is expressed at significant levels in dendrites and nuclei, we established 
primary hippocampal cultures from homozygous Tau-mEOS2 mice and used confocal imaging to 
visualize the mEOS2-tagged Tau in live neurons. We found that Tau-mEOS2 showed a strong 
axonal expression in mature (DIV18) neurons (n>10, 100%), with a gradient towards enrichment in 
the growth cone of distal axons (Fig. 4.2a). Tau-mEOS2 was further present in the somatodendritic 
domain (Fig. 4.2b), with very low levels in dendritic spines (Fig. 4.2c). Within the limit of 
detection, we did not visualize EOS-tagged endogenous Tau in the nucleus, suggesting that the level 
is either very low and/or that previously reported detection represented background reactivity (Fig. 
4.2d). Interestingly, as for the staining of WT neurons with anti-Tau antibodies, Tau was found to 
be expressed throughout the cell, with an enrichment in the axon. This shows that, even with a 
reduced level of Tau, the neuron is capable of maintaining an axo-dendritic gradient. This is 
important for treatment strategies aimed at reducing Tau levels [124]. 
 
To demonstrate that the endogenously expressed mEOS2-tagged Tau in the Tau-mEOS2 mice can 
be photo-converted, we assessed Tau transport in the axon. Time-lapse imaging revealed the 
bidirectional transport of Tau at about ~0.25 µm/s out of the region of interest (Fig. 4.2e). This 
value is lower than that previously obtained for over-expressed CFP-hTau40 in retinal ganglion cell 
neurons (0.4~0.6 µm/s), indicating that the transport of Tau is affected by expression levels and the 
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Figure 4.1 
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Figure 4.1 Generation of Tau-mEOS2 knock-in mice using the genome-editing tool TALEN. 
(a) Tau-mEOS2 knock-in strategy. Upper panel, murine MAPT locus. Lower panel, mEOS2 
cassette (in green) inserted in-frame down-stream of MAPT exon 12 using a linker sequence (in 
orange). (b) Homologous recombination of the donor construct into the target site using 
TALENs. A TALEN pair (in blue) targeting a sequence near the stop codon in exon 12 of the 
MAPT gene. The donor construct comprises a sequence encoding the photo-convertible 
fluorescent protein mEOS2 flanked by 500 bp each of the homologous arms. (c) Flanking PCR 
using two primer pairs (P1/P2, P3/P4) to identify mice that have integrated the donor construct 
by homologous recombination (HR) (Tau-mEOS2 mice) identifies two positive founders (#90 
and 120) in 120 animals obtained by micro-injection. (d) Western blot analysis shows that the 
size of Tau-mEOS2 is about 75 kDa, which is approximately 25 kDa larger than endogenous Tau 
as predicted, indicating correct targeting of mEOS2 into the MAPT locus. Wild-type (WT) and 
Tau knock-out (KO) samples were included as controls. (e) Dephosphorylation reveals three 
murine central nervous system isoforms in Tau-mEOS2 mice with a 2N:1N:0N ratio similar to 
that in WT mice. (f) qRT-PCR analysis reveals almost three-fold reduced levels of Tau-mEOS2 
compared to WT Tau (two-tailed unpaired Students t-test, ** P<0.01, n=3 per group). 
 
 
experimental system [125]. 
 
We were next interested in determining whether the axo-dendritic gradient is impaired when Tau is 
over-expressed, as is routinely done to study Tau. For this, we used hippocampal cultures at two 
stages of maturation: DIV5, when neurons are immature, and DIV18, when the neurons have 
developed mature spines. We over-expressed EGFP-tagged forms of human WT (hWT-Tau) and 
human P301L mutant Tau (hP301L-Tau), one modelling the form of Tau that accumulates in AD 
and the other the form of Tau that accumulates in FTD. Importantly, as for the Tau-mEOS2 mice, 
the EGFP tag was added to the carboxy-terminus of the two over-expression constructs. However, 
the fact that an exogenous promoter rather than the endogenous promoter was used to drive 
expression of hWT and hP301L Tau could potentially result in a different spatial specificity, as it 
has been shown in transfection studies that the 3' UTR of the Tau-encoding MAPT gene has a role 
in axonal targeting of the mRNA [126]. By DIV5, Tau was already found to be present in all major 
neuronal compartments (soma, axon and dendrite) in Tau-mEOS2 neurons (Fig. 4.3 a,b). Moreover, 
it was axonally enriched, displaying a proximo-distal gradient, similar to that found in hippocampal 
cultures from WT C57Bl/6 mice that were stained with the anti-Tau antibody Tau5 and a 
fluorescent secondary antibody (Fig. 4.3c).  
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Figure 4.2 
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Figure 4.2  Tau-mEOS2 is localized to axons, dendrites and the soma but excluded from the 
nucleus. Mature DIV18 hippocampal cultures from Tau-mEOS2 mice cotransfected with the 
spine marker Lifeact-RFP to reveal dendritic spines. (a) Tau-mEOS2 mice show a strong axonal 
expression of EOS-tagged Tau, with a gradient towards the growth cone of distal axons. (b) Tau-
mEOS2 is also present in the somatodendritic domain, (c) with very low levels in dendritic 
spines (zoom-in, white arrow: dendrite; yellow arrow: axon). (d) Within the limit of detection, 
EOS-tagged endogenous Tau cannot be visualized in the nucleus. (e) Time-lapse imaging of 
photo-converted mEOS2-tagged Tau reveals bidirectional transport of Tau in the axon at about 
~0.25 µm/s. Scale bar: 10 µm (a,b,c, d) and 15 µm (e). 
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 Figure 4.3  
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Figure 4.3   Tau in Tau-mEOS2 neurons shows an axo-dendritic distribution that differs 
from that of over-expressed Tau. Live cell imaging of Tau in Tau-mEOS2 hippocampal 
neurons (a,b) compared to neurons over-expressing EGFP-tagged hWT-Tau (d) and hP301L-
Tau (d,e) at DIV5 and DIV18 in culture, and to WT neurons stained with the pan-tau-specific 
antibody Tau5 (c). The yellow arrow indicates axons. Line profiles through an axon and a 
dendrite running in parallel displaying the relative intensity of Tau in these two compartments 
(b',c'). (f) Line profiles were established for the four experimental conditions to reveal the 
fluorescent Tau signal starting at a dendrite and then going through the soma and along the axon 
to its tip, demonstrating the altered axo-dendritic gradient in the over-expression systems. Scale 
bar: 50 µm 
 
By establishing line profiles through an axon and a dendrite running in parallel, the intensity of Tau 
in the axon was found to be approximately 2.5-fold higher than that in the dendrite both when Tau-
mEOS2 cultures were captured and when WT cultures were stained with the Tau5 antibody (Fig. 
4.3 b',c'). More generally, dendritic staining was found to be uniformly weak, whereas that in axons 
was generally more variable. Upon over-expression of either hTau-EGFP or hP301LTau-EGFP in 
WT neurons, both forms of Tau were found to accumulate throughout the neuronal cytoplasm, 
although the fluorescence intensity for the axon was much lower than that for the somatodendritic 
domain (Fig. 4.3 d,e). This was already evident at DIV5 and was maintained with neuronal 
maturation (Fig. 4.3 a-e, lower panel). We also established line profiles for all experimental 
conditions to reveal the fluorescent Tau signal starting at a dendrite and proceeding through the 
soma and along the axon to its tip. This not only demonstrated that the axo-dendritic gradient was 
inverted in the over-expression systems, but also revealed that the proximodistal gradient of Tau 
was abolished within the axon (Fig. 4.3f). Together these results demonstrate that, despite a 15-fold 
lower expression level, Tau-mEOS2 shows a distribution similar to that of endogenous Tau, which 
is distorted when Tau is over-expressed in its WT form or carrying a mutation (P301L) found in 
human tauopathy.s 
 
 
4.5.3 Spine localization of over-expressed P301L Tau is increased compared with that of over-
expressed WT Tau or endogenous mEOS2-tagged Tau 
  
Tau localization in the dendrite has previously been found to extend to spines; however, levels of 
endogenous Tau were reported to be low, unless Tau was over-expressed, causing it to enter spines 
in a phosphorylation-dependent manner [115,127]. To assess spine localization of Tau, we co- 
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Figure 4.4 
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Figure 4.4 Increased spine localization of Tau and reduced spine numbers in neurons over-
expressing P301L human Tau compared to WT human Tau over-expressing and Tau-
mEOS2 neurons. (a) Filamentous (F-) actin visualized with Lifeact-EGFP co-localizes with 
PSD-95 in dendritic spines (white arrows in cropped, zoomed-in images indicate spines). (b-d). 
Live-cell imaging of hWT-Tau and hP301L-Tau over-expressing neurons at three stages of 
neuronal maturation, DIV5 (b), 12 (c) and 18 (d), (plus zoom-ins) reveals that both forms of Tau 
are mainly excluded from filopodia. Spine localization of hP301L-Tau is more pronounced than 
that of hWT-Tau (b-d), which only becomes visible by increasing the gain (e). Endogenous Tau 
(Tau-mEOS2) is also targeted to spines, albeit at much lower levels (f). Spine counts do not 
differ between Tau-mEOS2 and hWT-Tau over-expressing neurons, but are massively reduced 
in hP301L-Tau over-expressing neurons (two-tailed unpaired Students t-test, ** P<0.01). (g) 
Scale bar: 20 µm (a), 50 µm (b-d), 10 µm (e,f) 
 
expressed EGFP-tagged Lifeact, a versatile marker to visualize F-actin [128], as a spine marker, due 
to its co-localization with RFP-tagged PSD95 in DIV18 WT neurons (Fig. 4.4a). 
 
Using live-cell imaging to assess hWT-Tau and hP301L-Tau over-expressing neurons at three 
stages of neuronal maturation (DIV5, 12 and 18), we found that although both forms of Tau were 
mainly excluded from filopodia within the limit of detection, they were targeted to dendritic spines, 
with a lower intensity of spinal compared to dendritic Tau, and a more pronounced spine 
localization of P301L Tau compared to WT human Tau (Fig. 4.4 b-d), as shown by applying a 
higher gain to expose spine localization (Fig. 4.4e). Endogenous Tau was also targeted to spines, 
albeit at much lower levels (Fig. 4.4f). Unambiguously identifying spine localization is easier in 
hWT-Tau and hP301L-Tau over-expressing neurons than in Tau-mEOS2 cultures, as in the latter 
only a fraction of neurons is fluorescently tagged, allowing a better discrimination against a 
background of non-fluorescing neurons. We next performed spine counts and found that these did 
not statistically differ between hTau-mEOS2 and hWT-Tau over-expressing neurons, but were 
massively reduced in hP301L-Tau over-expressing neurons (Fig. 4.4g). Hoover and colleagues 
previously reported no reductions in their P301L-Tau cultures, and whereas we observed 
approximately 95 spines/100 mm in WT cultures, they reported around 40 spines/100 mm. 
However, the two studies differ in several aspects: they transfected 0N4R and not 2N4R Tau, and 
they transfected at DIV7-10 and analysed the neurons at DIV21 [115,127], whereas we transfected 
the neurons only at DIV18 and analysed them at DIV19/20. Together, our findings reveal that even 
under physiological conditions, Tau is targeted to dendritic spines, and that over-expression of 
P301L mutant Tau causes a decrease in spine density. 
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4.5.4 FRAP analysis reveals a similar mobility of Tau in dendrites and axons, but in both 
compartments, Tau-mEOS2 is less mobile than hWT-Tau and hP301L-Tau  
 
We next used the FRAP assay to address the dynamics of Tau in DIV18-21 hippocampal cultures 
under over-expression conditions compared to the lower expression encountered in the Tau-mEOS2 
mice, and analysed the recovery profiles to determine the mobility and mobile fraction in the 
different neuronal compartments. It has to be considered that trafficking of molecules into the spine 
is unidirectional (from the dendritic shaft through the spine neck into the spine head), whereas in 
the axon and dendrite, Tau can move into the bleached area from both ends. The bleached spine is 
also much smaller than the bleached area of either the axon or dendrite, which generally results in a 
faster recovery. Therefore, the spine FRAP data were analysed independently from those obtained 
for axons and dendrites. 
 
We first determined the dynamics of hWT-Tau, hP301L-Tau and Tau-mEOS2 in the axon and 
dendrite (Fig. 4.5 a,b), and determined the mobility by calculating the diffusion constant t1/2 (the 
time required for the fluorescence to reach 50% recovery, with more mobile molecules displaying a 
smaller t1/2) and the mobile fraction (Fig. 4.5c). We found in both the dendrite and the axon that the 
mobility of Tau-mEOS2 was lower than that of either hWT-Tau or hP301L-Tau. We further found 
when either hWT or hP301L Tau was over-expressed, that the mobile fraction of Tau was between 
70 and 80% of the total pool, whereas for Tau-mEOS2, this fraction was reduced by a factor of two, 
possibly reflecting less efficient binding of Tau to microtubules when Tau is over-expressed. 
Interestingly, for any experimental condition, we did not observe a difference in the mobility or 
mobile fraction of Tau between axons and dendrites.  
 
We next determined the dynamics of hWT-Tau and hP301L-Tau in the spine (the Tau-mEOS2 
signal was too weak to be included in the analysis) (Fig.  4.6 a,b), and determined the diffusion 
constant t1/2 and the mobile fraction in this subcellular compartment (Fig. 4.6c). Because F-actin is 
a critical Tau-interacting protein and is enriched in spines, we specifically determined the mobility 
of F-actin (Lifeact-RFP) depending on the form of Tau being expressed. This revealed that although 
F-actin was less mobile than tau in spines, its dynamics was not affected by the form of Tau being 
over-expressed (which was also the case for dendrites and axons). Interestingly, there was a smaller 
mobile fraction of hP301L-Tau in the spines (55%) compared to that of hWT-Tau (80%). One 
explanation may be that more hP301L-Tau is tethered with F-actin in spines compared to hWT-Tau, 
which reduces its turnover rate in spines. We also found that whereas the mobility of hP301L-Tau  
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Figure 4.5 FRAP analysis in axons and dendrites of P301L and WT human tau over-
expressing and Tau-mEOS2 neurons.  (a) Grey-scale images of axons and dendrites from Tau-
mEOS2 neurons and hP301L and hWT Tau over-expressing neurons showing time-points before 
(pre) and after bleaching (t = 0, 10, 30, 60 and 100 s during fluorescence recovery). FRAP 
regions are indicated by dashed lines. (b) Recovery profiles and (c) FRAP analysis of Tau-
mEOS2 compared to over-expressed hWT- and hP301L-Tau in the dendrite and axon. In both 
compartments, the t1/2 of hTau-mEOS2 is higher than for either hWT-Tau or hP301L-Tau, and 
the mobile fraction is much smaller. (One-way ANOVA, *** P< 0.005; N>15). Scale bar: 20 µm 
(a). 
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Figure 4.6 
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Figure 4.6 Tau and F-actin dynamics in spines.  (a) Representative images of hP301L and 
hWT Tau over-expressing neurons showing time-points before (pre) and after bleaching (t = 0, 5, 
10, 15, 30 and 60 s during fluorescence recovery). (b) Recovery profiles and (c) FRAP analysis 
of hWT-Tau and hP301L-Tau together with the corresponding F-actin in spines. F-actin is less 
mobile than either form of Tau, and the mobility and recovery of actin are not affected by the 
form of Tau being over-expressed. There is a smaller mobile fraction in hP301L-Tau compared 
to hWT-Tau neurons (two-tailed unpaired Student's t-test, *** P< 0.005; N>20). 
   
in the axon and dendrite was higher than that of hWT-Tau (see above), it did not differ significantly 
in the spine. 
 
4.6 Discussion 
 
In our study, we present the Tau-mEOS2 mouse strain as an interesting system in which to 
investigate transport in neurons, under conditions of both physiologically and pathologically 
phosphorylated Tau. Regarding the significantly reduced Tau levels in Tau-mEOS2 compared with 
WT mice it remains to be seen whether these can be increased by generating Tau-EOS mice in 
which the EOS tag is added to the amino-terminus. In the Tau-mEOS2 mice described above, we 
observed a Tau gradient that differed from that of over-expression systems. A possible explanation 
is provided by a recent study that used photo-conversion of human WT Tau tagged with photo-
convertible Dendra2 followed by over-expression in relatively young cortical cultures to reveal an 
anterograde flow across the axon initial segment into the axon, but no flow back into the somato-
dendritic compartment, explaining axonal enrichment of Tau [129]. When Tau was 
hyperphosphorylated using the phosphatase inhibitor okadaic acid, the retrograde barrier was found 
to break down functionally, with Tau now flowing into the somato-dendritic domain where it is 
known to accumulate in AD [129]. Because okadaic acid can have multiple effects that go beyond 
Tau hyperphosphorylation, the study further used a '4KXGE’ Tau mutant mimicking constitutive 
phosphorylation, which again showed a functional break-down of the retrograde barrier and a 
relocalization of this form of Tau into the somatodendritic domain. This could potentially explain 
why over-expressed Tau accumulates in the somatodendritic domain, whereas endogenous Tau is 
more localized to the axon. However, there are also alternative explanations, as the over-expression 
of Tau could lead to a saturation effect, increasing the pool of Tau that is not captured by 
microtubules and hence starts accumulating in the somatodendritic domain.  
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In conclusion, with the Tau-mEOS2 mice we have developed a versatile tool that will allow for the 
monitoring of endogenous Tau in response to a range of stimuli. For example, neuronal activity has 
been found to drive physiological levels of Tau into the spine in a process that is incompletely 
understood and impaired by the peptide Αβ that drives AD [76]24. Here, the Tau-mEOS2 mice may 
be a tool to understand this process in more detail, using a system that avoids over-expression. 
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Chapter 5. Concluding comments 
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This PhD thesis resulted in one review [28] and three original research articles [93,115,130]. The 
first publication analysed a transgenic mouse line generated by me as part of this thesis that 
expresses a constitutively active form of Fyn that resulted in premature lethality, hyperactivity and 
an aberrant phosphorylation of the Fyn substrate Tau [93]. The second publication assessed the role 
of distinct phosphorylation sites and various domains of tau in its subcellular localisation, in 
particular the spine, by over-expressing these forms of tau in primary hippocampal neurons[115]. 
The third publication used yet another transgenic mouse strain, generated by me, applying the 
genome editing tool TALEN to target the endogenous tau-encoding MAPT locus with an mEOS2 
cassette that allowed me to juxtapose the behaviour of this form of tau to that of over-expressed tau 
(also analysed in the second paper), this time by focusing on the three subcellular compartments 
axon, dendrite and spine [130]. As a result of this work, I will be author on two further manuscripts 
that are in preparation, one addressing the role of tau in the axon initial segment, and the role Tau 
has in Fyn localisation using super resolution microscopy. 
 
As a starting point of my investigations, I contemplated the fact that the subcellular localisation of 
Tau and Fyn in neurons differs remarkably. Fyn is a membrane protein that is targeted to lipids raft 
on the plasma membrane of dendritic spines. In contrast, Tau is a microtubule-associated protein 
that is mainly expressed in the axons, where it binds to and stabilizes microtubules. Therefore the 
question is how the two molecules interact. This thesis provided insight into Fyn and Tau behaviour 
and also highlighted the difference between data generated by over-expression as compared to 
endogenous protein. There is more work to be done but the work presented here will provide 
guidance. 
 
Biochemical data from our and other laboratories has revealed that Tau is localized to the PSD, as 
shown in mature brain and also, primary neuronal cultures. This has been further confirmed by 
immunocytochemistry using Tau antibodies and live cell imaging using the Tau-mEOS2 mice 
generated in our study, revealing low levels of Tau in dendrites and spines under physiological 
conditions. However, the dendritic function of Tau is not well understood yet. In spines, Tau 
interacts with Fyn and PSD95, whose levels are increased by enhanced synaptic activity or Aβo 
treatment, indicating that Tau may act as a scaffold protein involved in synaptic plasticity or 
mediating excitotoxic signalling in AD.  
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Besides its well-known function in associating with microtubules, Tau has also been found to bind 
to actin through its MTB domain, to cell membranes with its N-terminal domain, or to diffuse freely 
in the cytosol. Therefore, Tau can also be categorized into four principal subcellular pools in 
neurons: the microtubule binding pool, the actin binding pool, the cytosolic pool and the membrane 
associated pool.  Of these four pools, only the function of microtubule binding is well understood. 
Previous research from our group had shown that in the absence of Tau or by overexpression a 
truncated form of Tau (ΔTau), the level of spine- targeted Fyn was largely reduced, indicating that 
Tau is required for Fyn localization in neurons. The following questions therefore arise:  Firstly, 
whether or not Tau and Fyn are co-transported?  Secondly, which fraction/pool of Tau is involved 
in Fyn targeting?  And thirdly at which step Tau is involved in trafficking of Fyn?  
 
Using immunocytochemistry of cultured hippocampal neurons, we since found that Fyn forms 
small clusters in dendrites and spines that colocalize with PSD95 (fig 5.1a). Interestingly, the 
intensity and density of Fyn clusters in Tau knockout neurons was significantly reduced (~50%).  
We further used sptPALM (Single-Particle Tracking Photoactivated Localization Microscopy) and 
found that the movement of Fyn in dendritic spines is more restricted than that in the dendritic shaft. 
Interestingly, in the spine of TauKO cultures, the mobility of Fyn increased significantly compared 
to that in wild-type cultures (data in preparation for publication), indicating that Tau is required for 
Fyn to be stabilized inside the spine as clusters, and without Tau, Fyn is less restricted and becomes 
more mobile.  Based on these preliminary data, we hypothesize that Tau is required for clustering of 
Fyn with PSD95 in the spine. 
 
Our work and the above preliminary data suggest the following experiments to be performed in the 
future:  
 
Experiment 1:  Generation of different mCardinal (a Far-red fluorescent protein) tagged constructs 
expressing either wild-type or mutant forms of Tau (lacking the ∆PXXP domain to perturb the 
Tau/Fyn interaction, ∆MTB to perturb the Tau/microtubule interaction, and expressing the R406W 
mutation to perturb the Tau/membrane interaction. Transfected hippocampal neurons will be 
analysed by sptPALM, co-expressing the constructs together with Fyn-mEOS2 in both Tau KO and 
wild-type neurons to determine whether wild-type Tau can rescue the targeting defect of Fyn in Tau 
KO neurons and which domain or subcellular pools of Tau are required for cluster formation of 
Fyn. Outcome: This experiment will confirm the requirement for Tau in clustering of Fyn and 
determine the domain(s) of Tau that are required for Fyn localization. 
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Experiment 2:  Generation of different EGFP- and mEOS2-tagged mutant Fyn constructs (e.g. 
lacking the SH2 (Fyn-PSD95 interaction), SH3 (Fyn-Tau interaction), or SH4 (Fyn membrane 
association) domains either alone or in combination, or a constitutively active mutant, FynCA)  
followed by live cell imaging and sptPALM in wild-type neurons to determine which domains and 
protein-protein interactions are required for cluster formation of Fyn. Outcome: This experiment 
will determine which domain(s) of Fyn are critical for clustering of Fyn into micro-domains. 
 
Experiment 3: Once it has been determined which domains are required for the targeting of Fyn 
with Tau, structured illumination super-resolution imaging39 of both Tau and Fyn can be performed 
to analyse the clustering of endogenous Fyn in both wild-type and Tau KO neurons. As we 
speculate that Tau is required for the clustering of Fyn into functional micro-domains (and Tau is 
affected by neuronal activation and Aβo), as a next logical step one can determine whether size and 
number of Fyn clusters in the spine are affected by either neuronal activation or Aβo incubation. 
Outcome: This experiment will reveal whether (as we expect) the size, number and mobility of 
these clusters depends on Tau and whether these three figures are modulated by both synaptic 
activation and Aβo.  
 
Together, these experiments will determine whether Tau has a critical role in Fyn clustering and 
whether this is affected by neuronal activation and Aβo incubation. In summary, a combination of 
mutagenesis studies, biochemical analyses, genome editing and novel microscopy techniques will 
elucidate where and how Tau and Fyn interact and what determines their subcellular localization. 
We expect that Tau has important scaffolding functions in the spine and that Fyn has a crucial role 
in as a sensor of both physiological and pathological stimuli. Understanding how these two 
molecules talk to each other will be essential to understand pathogenesis in tauopathies more 
generally, and the work presented here contributes to the foundation required to gain this 
understanding. 
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